Verisante - revolutionäre Technologien zur Früherkennung von Krebs - 500 Beiträge pro Seite

[M@trix]

Verisante Technology ist ein kanadisches Unternehmen, das Exklusiv-Lizenzen für Produkte zur Früherkennung von Krebs hält.

Kernprodukt ist derzeit "Aura" (siehe Foto), mit dem Melanome binnen einer Sekunde mit fast 100%iger Sicherheit festgestellt werden können. Hautärzte haben eine durchschnittliche Erkennungs-Rate von 69% - wenn der Krebs schon da ist...



In frühem Stadium kostet ein Hautkrebs-Behandlung jährlich 55.000 USD. Patienten die früh behandelt werden haben eine Überlebenswahrscheinlichkeit von 99%. Hat sich der Hautkrebs jedoch erst mal entwickelt, steigen die Kosten der Behandlung auf jährlich 110.000 USD und die Überlebenswahrscheinlichkeit sinkt auf 15%.

In Europa, Kanada und Australien soll "Aura" im kommenden Jahr auf den Markt kommen, 2013 dann auch in den USA.

Preis pro Gerät: 30.000 USD. Das ist viel Geld, allerdings kostet eine Biopsie auch rund 1.000 USD und ist wesentlich aufwendiger. Das Gerät rechnet sich für einen Dermatologen ca. nach einem Jahr.

Das Unternehmen hat sich seit November 2010 insgesamt 6,25 Mio. CAD über Kapitalerhöhungen besorgt und wird zur Kommerzialisierung von "Aura" voraussichtlich kein weiteres Kapital benötigen.

Neben "Aura" wird die Plattform-Technologie im Rahmen der "Core"-Serie auch zur Früherkennung von Lungen-, Darm-und Gebärmutterhalskrebs eingesetzt.

Bisher gab es kleinere Test-Studien mit sehr vielversprechenden Ergebnissen.

Hier ein ausführlicher Research-Report (IR) in Englisch, der auch Aspekte zum Marktpotenzial, Management und Wettbewerbern beinhaltet:
http://verisante.com/docs/verisante_zacks.pdf

Es gab zudem im April dieses Update:
http://www.verisante.com/docs/verisante_zacks2.pdf

Weiteres unter http://www.verisante.com/

Die Aktie wird in den USA OTC und in Kanada an der TSX gehandelt. Eine Handelsaufnahme in Deutschland wird in einigen Wochen erfolgen.

WKN / ISIN: A1JFNF / CA92346G1046



Kurs, Chart und Diskussion in Kanada:
http://www.stockhouse.com/tools/?page=%2FFinancialTools%2Fsn…

Marktkapitalisierung aktuell: 45,5 Mio. CAD (bzw. bei EUR/CAD von aktuell 1,35 rund 33,7 Mio. EUR)

Der Verisante-CEO im Juni bei Fox News:



Und hier ein Report bei BTV:



Verisante ist tendenziell ein mittel- bis langfristiger Übernahmekandidat. Bald kommt eine weitergehende Studie zur Effizienz von "Aura". Wenn diese abermals die bisherigen guten Werte bestätigt, sollte der Wert größere Aufmerksamkeit generieren. In Deutschland gibt es bislang keine Diskussionen zu der Aktie. In Kanada und den USA kam vor allem durch einen jüngeren Beitrag von Bob Moriarty (321gold.com) Bewegung in den Wert. Hier der Artikel:

http://www.321gold.com/editorials/moriarty/moriarty061111.ht…

In den letzten 4 Tagen kam es zu einer spekulantengetriebenen Kursexplosion, die aber nach einer zeitnahen "No news"-Meldung durch Verisante wieder in sich zusammengefallen ist.

Das Management erscheint hochgradig qualifiziert und weiß Investoren zu überzeugen. Die Technologie könnte sich zu einem neuen Standard in der Krebsfrüherkennung entwicklen. Verisante arbeitet hier auf einen weiteren Ausbau des Produktportfolios hin.

Der Wert ist sehr markteng und naturgemäß riskant. Ich bin investiert, weil das Unternehmen langfristig über immenses Potenzial verfügt.

Machen Sie Ihre eigene Due Diligence.

[Gulliver]

Interessante und informationshaltige Einführung zur Aktie - liest sich erstmal ganz vielversprechend...

...ich habe jedoch schon einige Medtech-Unternehmen mit revolutionärer Technologie gefunden, die sich später nicht am Markt haben durchsetzen können... trotz vermeintlich überlegener Technologie, einem soliden Preisleistungsverhältnis und mangelnder Konkurrenz...

...aktuelles Beispiel ist CYTX, die von ihrem Celution auch nicht genug Geräte abgesetzt bekommen...

[M@trix]

Hallo Gulliver,

das ist durchaus richtig. CYTX kannte ich dato nicht, denke aber, dass die beiden Werte schwerlich miteinander vergleichbar sind. Der Börsenwert von CYTX liegt 5-mal höher und das Produktspektrum und die Zielgruppe ist völlig anders gelagert.

Wichtig ist m.E., dass das Produkt unzweifelhaften großen Nutzen stiftet und im Idealfall die Gesundheitssysteme finanziell entlastet. Beides ist bei VRS gegeben. Daher denke ich, dass VRS seinen Weg gehen wird.

Mit besten Wünschen,
M@trix

[T.Hecht]

Antwort auf Beitrag Nr.: 41.821.095 von M@trix am 21.07.11 09:03:21

Kernprodukt ist derzeit "Aura" (siehe Foto), mit dem Melanome binnen einer Sekunde mit fast 100%iger Sicherheit festgestellt werden können.
Bisher gab es kleinere Test-Studien mit sehr vielversprechenden Ergebnissen.
..na immerhin!

Der Knaller ist natürlich das Bild. Ich gehe mal davon aus, dass es ein Handheld ist. Wenn ich als Hautarzt mit dem Ding die Hautoberfläche abgescannt habe, habe ich mir tatsächlich ein gutes Bild gemacht. Allerdingsbraucht die Behandlung deutlich länger, da ich mit normalem Schauen eine größere Hautpartie scanne. Vielleicht liegt ja in dem genaueren Schauen die höhere Erfolgsquote begründet?
Wozu brauche ich das Ding dann aber?

[MrRipley]

Hallo M@trix, schön, dass Du mal wieder reinschaust.

P.S.
Sino macht wohl das Gap wieder zu, der SI hat am Dienstag etwas Interessantes geschrieben bzgl. Paulson & Co.

[M@trix]

@MrRipley
Ja, Heirat und inzwischen zwei Kinder haben den Fokus etwas verändert... ;-)

Das ging ja schneller als gedacht:

Verisante Joins Frankfurt Stock Exchange

VANCOUVER, BRITISH COLUMBIA--(Marketwire - 07/21/11) - Verisante Technology, Inc. (TSX-V:VRS - News)(OTCQX: VRSEF)(PINK SHEETS:VRSEF - News)(Frankfurt:V3T - News) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that the Company has begun trading on the Frankfurt Stock Exchange, one of the world's largest trading centres for securities.

"Verisante is steadily moving towards obtaining a CE Mark by the end of the year, which will allow us to begin marketing the Aura™ device for skin cancer detection in Europe," said Thomas Braun, President and CEO. "Europe is a major market for the Aura with 21,000 dermatologists and 450,000 general practitioners. We will be attending conferences and trade shows in Europe and listing on the Frankfurt Exchange makes sense as investor awareness will emerge as a result of our product advertising and marketing efforts."

Investors can find current financial disclosure and Real-Time quotes for Verisante's equities on http://www.boerse-frankfurt.de under the Stock Symbol V3T (or ISIN CA92346G1046).

Investors can also find the Company's corporate video and Zacks Investment Analyst reports on the Company's website at www.verisante.com.

http://finance.yahoo.com/news/Verisante-Joins-Frankfurt-iw-3…


Here we go.

[M@trix]

Update von ZACKS:

Dermatologist Shortage Offers Huge Opportunity for Verisante

July 21, 2011

There was an interesting article in the April 27, 2011 edition of Men's Health magazine which highlighted not only the skin cancer epidemic in the U.S. but also the seriousness of the shortage of dermatologists. For those that do not understand how (life-threateningly) serious the problem is, the article, which documents how two skin cancer victims had to endure month-long waits (as the cancers progressed) to see a dermatologist, is an excellent wake-up call (link here: http://www.menshealth.com/health/skin-cancer-appointments).

The problem is two-fold. The first is that the incidence of skin cancer (including melanoma) continues grow very rapidly. In the article Brett Coldiron, M.D., characterizes the growth in U.S. skin cancer cases as "an epidemic." Skin cancer accounts for about one-half of all cancers in the U.S. and roughly 1 in 5 Americans will be diagnosed with skin cancer in their lifetime. Melanoma, while accounting for only about 3% of skin cancer, causes 75% of skin cancer deaths.

The second problem, which likely is largely unrealized by the general public, is that there are not nearly enough dermatologists to handle the skin cancer epidemic. It's estimated there are only about 10k dermatologists in the U.S. (and many of these - as much as one-third, only focus on cosmetic procedures and do not screen for skin cancer) with only a slow trickle coming out of medical school each year. This has caused a backlog of patients waiting to see a dermatologist - and the wait can be many, many (as in 6 to 18) months. The problem is especially pronounced in rural areas.

One way dermatologists have been trying to reduce patient wait time and increase throughput is by having a physician assistant see patients. The current "gold-standard" for skin cancer screening ("ABCD" method) is subjective and highly prone to error, especially for less experienced physicians - this poses an especially significant potential problem when non-MD's are the ones doing the screening. Dr. Coldiron notes, "They are not as well trained. They could miss something." The article cites a study that found 23% of dermatologists contacted used an "extender" (i.e. - assistant) to look for skin cancer.

Verisante Technology, a company that we initiated coverage on earlier this year, is specifically addressing the issues of rampant growth in the incidence of skin cancer and too few professionals to handle the epidemic. Their Aura skin cancer detection device has shown in preliminary data to be more accurate than "ABCD", even when "ABCD" is performed by a dermatologist. The device, which provides yes-no diagnosis (i.e. - non-subjective), has the ability to revolutionize skin cancer diagnosis and, even in the hands of "extenders", would allow for more reliable screening than the current gold-standard.

With no end in sight to the dearth of dermatologists and continued escalation in the number of skin cancer cases (see graph below), more and more general physicians (i.e. - non-dermatologists) will need to be able to accurately diagnose skin cancer - and Aura could be the way to do it. With high-throughput scanning (under 1 second per lesion), Aura also affords accurate full-body scans in just minutes, an impossibility with "ABCD".

Dramatically Escalating Incidence of Melanoma (SOURCE:SEER)

Incidence of Melanoma in U.S.



Verisante expects to launch Aura in Canada and Australia later this year - both of which have similar (or even more severe) shortages of dermatologists (see charts below). Both countries also have vast swaths of rural areas, where the problem is especially pronounced. We think Aura could make its U.S. entrance sometime in 2013. Although there are other technologies that have either been recently introduced or are in late-stage development that would directly compete with Aura, the market still remains almost completely up for grabs. And based on the huge market size and what we expect to be certain competitive advantages (speed, versatility for all types of skin cancer, greater accuracy, smaller probe), we believe Aura will be very well received and expect sales to ramp very quickly following launch.





http://www.zacks.com/stock/news/57477/Dermatologist+Shortage…

[M@trix]

Verisante Obtains Iso Certification of Quality Management System for Medical Device Manufacturing

finance.yahoo.com/news/Verisante-Obtains-Iso-iw-1813165730.html?x=0&.v=1

[wallstone]

Hier noch was gefunden:





Erstvorstellung 09.06.2011
Small-cap-news.de

Rating: kaufen
Risiko: mittel
12-M.-Ziel: 2,00 CAD
Aktienkurs: 0,56 CAD
Stoplimit: 0,45 CAD
Stand: 08.06.21:10 Uhr
Börsen: TSXV ( Toronto)

Unternehmensinfos:*
Land: Kanada
Geschäft: Medizintechnik
CEO: Thomas Braun
Tel. [phone]
Web: www.verisante.com
Adresse: 306 -2309 West 41 st Avenue, Vancouver BC
Aktienzahl:50,360 Mio.
Market Cap: 27 Mio. CAD
* Die Informationen beruhen auf Angaben der Gesellschaft und auf den veröffentlichten Filings.



Verisante Technology Inc. – Milliarden Potential mit Krebs Früherkennungs Scanner
• Weltweites Anwendungspotential
• Innovatives Scan System zur Früherkennung von Krebs
• TSX notiert und streng reguliert
• Sehr gut finanziert mit über 5 Mio. CAD Cash
• Verisante Technology Inc.: Symbol: VRS (TSX) Kurs: 0,56 CAD Kursziel: 2,00 CAD

Hautkrebs ist die weitläufigste verbreitetet Form von Krebs. Zudem ist sind Hautkrebserkrankungen die am schnellsten wachsenden lebensgefährlichen Erkrankungen überhaupt. In den USA sind 50% der Bevölkerung über 65 Jahre in einer Form von Hautkrebs betroffen, zudem stirbt jede Stunde in den USA ein Patient in Folge von Hautkrebserkrankungen. Wird Hautkrebs in einem frühen Stadium erkannt, liegt die Überlebenswahrscheinlichkeit bei über 98%, bei später Diagnose reduziert sich die Wahrscheinlichkeit auf nur noch 15%. Alleine die jährlichen Behandlungskosten nur in den USA liegen bei über 2,5 Mrd. US Dollar, wobei die Behandlungskosten im späteren Stadium 20 mal höher sind, als eine Behandlung nach frühzeitiger Erkennung.
Verisante Technologie Inc. Frühdiagnosesystem zur Krebserkennung mit weltweitem Mrd. Absatzpotential
Versisante Technolgies ist eine Medizin Technologie Firma, die das Versisante Hautkrebs Früherkennungssystem ab 2011 weltweit vermarkten wird. Mit Verisante TM Aura und Verisante TM Core hat die Gesellschaft zwei weltweit gültige Patente. In Zusammenarbeit mit der Krebsdiagnostikabteilung der Universität von British Columbia wurde die Technologie bereits erfolgreich an über 1000 Patienten getestet.

Das wissenschaftliche Team von Verisante hat zudem in den letzten Jahren zahlreiche Auszeichnungen im Bereich Krebsheilung bekommen. Versiante verfügt über ein weltweit führendes Team im Bereich der Krebs Früherkennung. Hierzu gehören u.a. Prof. Dr. Harvaey Lui, Chef der dermatologischen Abteilung der University of BC, Prof Dr. David Mc Lean, President des Krebsfrüherkennungsteams von Kanada. Sowie Prof. Dr. Stephan Lam, Chef der Lungenkrebsabteilung der Universität von BC.In den letzten Jahren wurde zum einen der notwendige Scanner sowie die erforderliche Software weiterentwickelt, um im Jahr 2011 die Marktreife zu erlangen.

Kommerzialisierung des Verisante Früherkennungssystems
In den nächsten Monaten arbeitet das Management daran, die behördlichen Genehmigungen für den offiziellen Vertrieb in Canada zu bekommen. Im Anschluss daran wird man die Märkte in Europa und USA angehen und dort die entsprechenden Genehmigungen zum Vertrieb beantragen. Die Serienproduktion sollte im Frühjahr 2012 beginnen, womit dann wohl auch die ersten nennenswerten Umsätze erwirtschaftet werden. Bereits im Jahr 2013 rechnet Zacks Equity Research mit Erlösen deutlich über der 10 Mio. Dollar Marke und dem Erreichen der Profitabilität.
Fazit:Verisante Technologie hat mit dem System zur Frühdiagnose von Krebs das Potential, einen Blockbuster am Markt zu etablieren! Die Gesellschaft ist mit 5 Mio. Dollar Cash gut finanziert und sollte bereits Ende 2011 bzw. Anfang 2012 die ersten Umsatzerlöse erwirtschaften. Bereits im Jahr 2013 rechnet Zacks Equity Research mit Umsätzen von über 15 Mio. Dollar und einem Gewinn von 7 Cent pro Aktie. Im Vergleich zu herkömmlichen Medikamenten ist das Zulassungsverfahren, um eine behördliche Vertriebsgenehmigung zu erhalten, um ein vielfaches schneller. Somit kann auch damit gerechnet werden, dass der internationale Roll Out des Produktes bereits im Jahr 2012 beginnt. Das weltweite Absatzpotential liegt bei einigen 100 Mio. Dollar pro Jahr, wobei eine extrem hohe Umsatzrendite erwirtschaftet werden kann. Im Peergroupvergleich ist Verisante zudem schon im jetzigen Status mindestens um den Faktor 3-5 unterbewertet. Die Aktie könnte sich in den nächsten Jahren durchaus zu einem Tenbagger entwickeln. Auf dem aktuellen Niveau von 0,56 CAD sehen wir auf Sicht von 12 Monaten ein Kursziel von 2,00 CAD
Verisante Technology Inc.: Symbol: VRS ( TSX) Kurs: 0,56 CAD Kursziel: 2,00 CAD

[M@trix]

Verisante Engages Manufacturing Partner and Provides Operational Update for Verisante Aura(TM) Device for Skin Cancer Detection
8/3/2011 10:01:21 AM - Market Wire

Verisante Currently Exhibiting at the American Academy of Dermatology Summer Meeting in New York from August 3-7

VANCOUVER, BRITISH COLUMBIA, Aug 03, 2011 (MARKETWIRE via COMTEX News Network) --

Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF)(PINK SHEETS: VRSEF)(FRANKFURT: V3T) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that it has engaged StarFish Medical Inc. to provide engineering services and expertise to develop the Company's initial product, Verisante Aura(TM), for manufacturing.

Verisante Aura(TM) is a novel, multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. This system provides valuable information about the chemical composition of the skin quickly and non-invasively. Verisante Aura(TM) scans for 21 biomarkers instantly, providing immediate, accurate results on benign and malignant lesions. The Aura(TM) requires the use of a disposable end cap to be replaced after each use for health and sanitary reasons. Therefore, in addition to revenue from initial sales of the device, Verisante will also have a recurring revenue stream.

Thomas Braun, CEO of Verisante Technology, Inc. said: "We are very pleased to have StarFish Medical Inc. as a strategic partner to facilitate the development of our lead product, Verisante Aura(TM). StarFish has a proven track record in medical device development and manufacturing and has established strong compliance with all industry standards, including compliance with ISO 13485:2003, CE Mark, and FDA GMP regulations."

Last week, Verisante announced that it has successfully completed the certification process for ISO 13485:2003, an internationally recognized quality management standard. The certification is a confirmation of the Company's ability to design and manufacture medical devices.

Operational Update for the Aura

"Our next major milestones for the Aura(TM) are to apply for regulatory approvals in Canada, the European Union and Australia," said Mr. Braun. "With our strategic partner preparing for manufacturing over the next several months, we will be increasing our focus on marketing the Aura(TM) in the territories where we obtain regulatory approvals. Skin cancer is the most common cancer and there are 21,000 dermatologists and 500,000 GPs in Europe. We see a large unmet need for a device like the Aura(TM) that can assist doctors with early detection."

The statistical analysis of the Aura(TM) clinical study pursuant to a Collaborative Research Agreement between the Company and the University of British Columbia Department of Dermatology has been completed. The study on clinical trial data collected during the past six years by the Aura(TM) clinical prototype will be submitted by the research team to a peer reviewed journal and the results will be announced in conjunction with publication. At this time the publication date is not known.

The Company will have seven fully functioning Aura(TM) prototypes in early Q4 that will be available for demonstrations and clinical studies. Verisante currently has nine engineering and scientific personnel working out of the Company's technical office in Richmond, BC.

The Company continues to maintain a strong cash position with proceeds from the exercise of outstanding warrants following the Company's $5 million private placement in April. Since the beginning of the year, approximately 4.7 million warrants have been exercised for direct proceeds to the Company of just over $1.3 million. Verisante currently has 59,785,117 shares, 18,571,600 warrants, and 3,645,000 options outstanding.

Verisante is currently exhibiting at an information and educational booth (#431) at the American Academy of Dermatology Summer Meeting in New York from August 3-7.

About StarFish Medical Inc.

For more than ten years, StarFish has provided practical and innovative solutions in all aspects of medical device design and manufacturing, from product definition and technical engineering to formal product development and volume production in a quality environment. StarFish, an ISO 13485 certified company, provides practical turnkey solutions to medical device companies all over North America. The company's cross-functional team offers expertise in engineering physics, electronics, software, firmware, mechanical engineering, industrial design and manufacturing transfer. http://www.starfishmedical.com

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura(TM) and Core(TM) have not yet been approved for sale. The Company anticipates Health Canada approval for the Aura in late 2011.

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contacts: Verisante Technology, Inc. Thomas Braun President & CEO [phone] [e-mail] www.verisante.com

SOURCE: Verisante Technology, Inc.

mailto:[e-mail] http://www.verisante.com

Copyright 2011 Marketwire, Inc., All rights reserved.

[M@trix]

Why invest in Verisante Technology, Inc (VRS:CA)

Skin cancer, the most common cancer in Canada

http://finance.yahoo.com/news/Dermatologist-Shortage-Offers-…

The Core and ClearVu Elite pilot study showed very significantresults - when one combines the rapid Raman Core with the fluorescenceClearVu one has 96% sensitivity and 91% specificity. the endoscopemarket is $5 billion per year and ours is the best in the world by amargin of 50%. that has to be worth something - and VRS has a marketcap of only $50 million.

Mela was $12 per share pre-approval ($250 mm market cap) and theywere only going after melanoma which is less than 5% of skin cancers -the Aura does all skin cancers - a market 20 times bigger than Mela's -not including the endoscope market! The MELA analysts (Roth, Rodman andBrean Murray) were estimating the market for melanoma screening to beworth up to $900 million per year in the US - the Global endoscopeequipment market is much bigger than that.

Australia alone has 1 million doctor encounters peryear for non-melanoma skin cancer. if one's device does not work fornon-melanoma skin cancer one is missing 95% of the market. Germany pays150 Euros for skin cancer screening as part of their public healthcare. Poland, France, Italy, Spain, Austria and all of the Scandinaviancountries are also good markets for the Aura.

[...]

https://www.stockhouse.com/Blogs/ViewDetailedPost.aspx?p=119…

[M@trix]

Overview of the AGM for VRS

"In attendance were Fireslayer96 and myself among about 10 investors and 3-5 VRS employees. No Board members were present.

It is fair to say that HC approval will likely happen and be announced in September. I do not expect any major announcements in August because TB mentioned that no one will likely take notice.

The head office is undergoing a facelift to create a consistent brand presence for analysts. TB says that a famous analyst could rocket the share price from .70 to $7. Obviously, he is quite confident in the product.

Clearly, TB is quite cash conscious and mentioned that he went to NY to talk with investors while having a booth at the summer meeting. Otherwise, it wouldn’t make much sense to attend when there is no working prototype or approval. When there is, he expects a line-up around the room to get a suspicious mole scanned.

Interestingly, the production of The Aura is happening through StarFish because they have the infrastructure and quality assurance measures in place. It will also cost the company less cash to assemble the product at an existing facility rather than doing it themselves. Minimizes the risk for having a facility and hiring employees.

1 million in warrants were exercised in the past 2.5 months. VRS has $5mil in the bank and they do not anticipate a need for another PP to achieve commercialization.

No mention of the 1000 lesion study. However, since the research has been done, he feels that the stats have gone up considerably because of technological advancements made in the instruments (lens improvements etc.)

CE Mark (Euro) and Australia have a reciprocal agreement. So TB sees no issue with getting into Australia. Interestingly, Brazil and Mexico are on the VRS map for 2010. Approval process is more simplified and skin cancer rates are quite high.

Mela approached VRS at the summer meeting in New York and certainly want what VRS has, asking to buy it. Not in a serious way it seems.

Discussion came up about FDA Approval. Although respectful, TB discussed the FDA approval process as being what I interpreted as antiquated. However, he has a stack of public documents from Mela’s experience that will help considerably.

Clinical prototype in less than a year for the Core and two years of testing needs to be done prior to any discussion on approvals.

On a side note, I was impressed with TB’s level of expertise in all areas of the company and the research he has done in general.

It is not a matter of “if” but “when” folks. IMHO."

http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=VR…

[M@trix]

In dieser Woche wurden die Aktien aus dem private placement vom April handelbar, d.h. die Sperrfrist hat geendet. Da es immer Investoren gibt die dann verkaufen möchten/müssen und zudem die Börsen massiv unter Druck standen/stehen, konnte man VRS-Aktien zu Spottpreisen kaufen. Habe selbst welche zu 0,53 CAD nachgelegt. Nun dürfte es bis in den September seitwärts gehen. Dann könnten höchstrelevante News (Studienergebnisse) kommen. Wenn dann das Börsenumfeld halbwegs passabel ist, wird die Aktie wieder in Richtung 1 CAD laufen.

M@trix

[M@trix]

Secrets of selling medical devices

Mary Teresa Bitti Aug 23, 2011 – 8:10 AM ET

Thomas Braun, CEO of Vancouver-based Verisante Technology, Inc., is one step closer to bringing the Verisante Aura, a non-invasive early skin cancer detection device developed by Canada’s leading dermatologists and cancer specialists, to market. The company, which has an exclusive licensing agreement with the BC Cancer Agency to manufacture the device, has recently received ISO certification and is awaiting Health Canada approval in order to start marketing the medical device this year. Since Health Canada’s requirements for medical devices are in alignment with those of Australia and Europe, the plan is to hit all three markets in short order. Mr. Braun explained to Mary Teresa Bitti what it takes to commercialize a new medical technology.

Q What are the potential impacts of the technology?

A In Canada, there is a one in six chance of getting skin cancer in your lifetime, but most of those people are over age 65 because it is the result of a lifetime of sun exposure. At the same time we have rapidly escalating health care costs and we are facing a shortage of dermatologists and general practitioners. So we need devices that can be used by technicians or physicians’ assistants to leverage the doctor’s time. This device reduces the amount of time it takes to diagnose skin cancer and it also reduces the biopsy ratio. Right now based on dermatologists just examining patients with their eyes, they have a biopsy ratio of 30 to one. Our device reduces that ratio to 6: 1 with nearly 100% sensitivity. When you catch a melanoma early, you pay $5,000 for treatment, which typically involves surgery to remove it and results in a 99% survival rate. If it progresses to Stage 4 and metastasis the cost for treatment is $110,000 with survival rates dropping to 15%.

Q What led you to launch Verisante Technology? How did you connect with the BC Cancer Agency?

A The concept of being able to image cancer like an ultrasound or a CAT scan images other diseases was so intriguing I thought it was a huge winner and technologically feasible. So I launched Verisante Technology in 2006. We worked on this for three years, had seven patents and went public. We had always wanted to work with the BC Cancer Agency but they were very advanced into a clinical trial and at that time they didn’t need an industrial partner. It was only after they had completed a six-year clinical trial and scanned 1,000 lesions that they felt they had sufficient evidence the technology worked and it would be a commercial success that they started looking for a partner. We were the only skin cancer imaging company in Canada and one of the few in the world and we happened to be local. We had just completed an IPO that raised $1.5-million at a difficult time. They liked the idea of being able to license the technology to a public company so that there is transparency.

Q Is this kind of partnership the way of the future for medical innovations?

A Big companies have the resources to develop their own technologies. Smaller companies don’t. This technology had been in development by the BC Cancer Agency and UBC for more than 10 years and was supported by the BC Cancer Foundation, the Canadian Cancer Society and Canadian Institutes for Health Research. A lot of time and money had already been spent. They have the infrastructure. I don’t know if you could raise money from investors and say to them we have a 10-year time horizon.

Q What are the steps to take a medical technology to market?

A It starts with a unique proprietary platform technology that addresses an unmet need and that you can build a multi-million-dollar business on with multiple shots on goal. In this case, there is also an endoscopic version, which has already proven to work for early detection of lung cancer. The device has to save lives and money because ultimately you have to convince doctors, hospital administrators, insurance companies – all of the decision makers – that there is a strong economic case to adopt the technology. You also have to have a strong value proposition and competitive advantage that will attract funding. Once you have the money, you can hire the engineering people you need, the sales and marketing people, the regulatory affairs people and start to move the project along. Not only do you have to build this thing, run clinical trials and get it ready for manufacturing, in Canada you also have to get ISO certification. Then you have to do safety testing. You have to show your device won’t affect other medical devices in a hospital or doctor’s office and that it itself won’t be affected by electromagnetic radiation emitted by computers and other devices around it. Once the safety testing is done, you can apply for Health Canada approval. Canada’s system is very much in alignment with Europe and Australia, so once you tick all those boxes you can seek regulatory approval in each of those countries.

Q Why do you think you have been so successful in attracting funding?

A In 2011, we raised more than $7-million. The reason we have that high level of investor interest is because people see the value proposition. From the outset, we created a strategic pathway for regulatory approval that dovetails with a marketing pathway that will lead to early revenue. A lot of companies are focused on the U.S., the world’s largest market, but it’s also the hardest to get into. The guidance we got from the FDA was to go to the U.S. after we had approval in Canada, Europe and Australia because then they will view us in a much more favourable light.

Q Where do you go from here?

A The plan is to get everything done in order to have approval here in Canada, Australia and Europe by the end of the year. Once safety testing is done – and it should be in August – we will then apply for approval with Health Canada and initiate the process to get into Europe. You need approval before you can start marketing it. Otherwise you have to have a warning sign that says this product is not approved and potential buyers won’t be interested. It will take time to ramp up production and deliver. We are looking at early next year for delivery and closing sales. We’ll be attending a dermatology conference in Lisbon in October and Medica, the world’s largest medical device tradeshow, in Dusseldorf in November. We’ll look at distributors in Europe to start introducing the device to people. Australia will also be a huge market. It has the most cases of skin cancer in the world. Two-thirds of the population gets skin cancer at some point in life and there are some one million doctor visits per year to get screened for skin cancer. As a result, there are chains of walk-in skin cancer screening offices. We will be busy selling into all of these markets.

http://business.financialpost.com/2011/08/23/secrets-of-sell…


Here we go.

[M@trix]

Lesenswert:

Management’s Discussion and Analysis
Quarter ended June 30, 2011

https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf…

[M@trix]

VRS läuft gegen den schwachen Markt exzellent. Es stehen mehrere Meilensteine an, die in Kürze erreicht werden dürften, vor allem natürlich die Zulassung zum Vertrieb in Kanada, Europa und Australien. Dann dürften wir in neue Kursregionen vorstoßen.

Da es inzwischen kleinere Umsätze in Frankfurt gab, sollte ich nicht mehr der "einzige deutsche VRS-Aktionär" sein. Wer ist noch dabei?

Hier noch was zum Thema:

Heller Hautkrebs - die Zahlen steigen
http://german.irib.ir/nachrichten/wissenschaft/item/130205-h…

[M@trix]

Dank der Börsenkapriolen konnte ich heute meine Position günstig signifikant aufstocken. Kleine Werte wie Verisante sind immer anfällig für große Schwankungen. Da gilt es cool zu bleiben.

Verisante ist auf dem richtigen Weg. In einigen Monaten wird man sich sehr wahrscheinlich wünschen, wieder zu solchen Kursen kaufen zu können... Schon bald werden relevante positive News kommen.

[M@trix]

Zacks hat das Kursziel für Verisante von 2,25 CAD auf 2,65 CAD angehoben. Auszüge aus dem Research-Report:

- Verisante exited the quarter with CDN $4.9MM in cash and liquid investments

- Results of a small (26 patients) pilot study which used Verisante's Raman system technology, combined with white light and fluorescence bronchoscopy (technology which Verisante acquired in June) for the early detection of lung cancer were published in the July issue of the Journal of Thoracic Oncology. Results showed that when Verisante's Core lung cancer detection device (using Raman technology) is combined with the ClearVu and ClearVu Elite endoscopy system (which Verisante acquired) the number of false positives were reduced by over 75% compared to traditional endoscopic methods.

- Gaining ISO certification was the most significant near-term milestone to gaining regulatory approval of Aura in Canada, Europe and Australia - the expected initial markets for Aura. With the ISO certification now in-hand, Verisante can begin to finalize the required deliverables to gain Health Canada approval - which could be filed with regulators in the coming weeks. The company expects Aura to be approved for sale in Canada before the end of 2011.

- Verisante will have information booths at the 20th Congress of the European Academy of Dermatology and Venereology in Lisbon, Portugal in October and at Medica 2011 in November. Medica is the world's largest international medical trade show.

-Increasing the assumed price point for Aura had the effect of moving our revenue estimates for 2012, 2013 and 2014 (the latest year we model) from CDN $3.8MM, $15.6MM and $36MM to CDN $5.4MM, $21.2MM and $48.3MM currently. We have also made some adjustments to projected operating expenses and share count outstanding. The net result was EPS in 2012, 2013 and 2014 moving from CDN ($0.05), $0.05 and $0.18 to CDN ($0.05) - unchanged, $0.07 and $0.20 currently.

- With our 2014 EPS estimate moving from CDN $0.18 to $0.20 our valuation for Verisante has moved from approximately $2.25/share to $2.60/share (U.S.$ / CDN $ exchange rate remains at approximately 1/1). While the stock is up 97% since our February initiation, with the shares currently trading at $0.77, we continue to believe the stock is undervalued and are maintaining our Outperform rating on Verisante.

http://finance.yahoo.com/news/Encouraging-Developments-zacks…

[M@trix]

MelaFind Approval Is Positive for Verisante

September 26, 2011
Brian Marckx, CFA

This morning MELA Sciences (MELA) announced that the FDA issued an approvable letter in response to its application seeking regulatory approval for its MelaFind skin cancer detection device. The approvable letter requires MELA to finalize their labeling, package insert, users guide, training program and clinical protocol for a post-approval study before the agency will grant approval. MELA held a conference call this morning and noted that they expect to have everything finalized for a planned Q1 2012 U.S. launch.

As a reminder, MelaFind has been tied up in the regulatory approval process since MELA's June 2009 initial filing as a result of less than compelling clinical trial data. In clinical trials MelaFind was shown to have 98% sensitivity but only 9.5% specificity. Specificity was (statistically) significantly higher than that of dermatologists (3.7%) but the data did not impress well on regulators. In March 2010 the FDA returned with an approvable letter and later convened an advisory panel to weigh in on the decision whether to approve. After digging into the details of the data, the FDA concluded that MelaFind was actually less accurate than dermatologists in detecting melanoma. The agency characterized the benefit seen in the data as “clinically meaningless” as the device not only does not reduce the number of biopsies, it actually increases the number that doctors would need to perform.

Despite this, the FDA advisory panel actually voted 8 – 6 in favor that MelaFind is effective, 10 – 6 in favor that it is safe, and 8 – 7 in favor of approval based on the potential benefits outweighing the risks. While this morning's approvable letter still requires MELA to clear a few hurdles, they are relatively low and FDA approval now seems highly likely.

While MELA will have first mover advantage in the U.S. (we model Aura to launch in the U.S. in 2014), in our opinion, MelaFind's impending FDA approval is an overall positive event for Verisante and its Aura skin cancer detection device. We point to two reasons why this is good news for Verisante;

1) MelaFind's clinical data showed 9.5% specificity (i.e. - MelaFind's false positive rate was very high) which compares to specificity of about 70% (with sensitivity of 100%) for Aura from top-line data from a 1,000+ lesion study. While the full data set may show lower accuracy than the top-line data did, FDA has indicated with it's impending approval of MelaFind that the bar is set very low which may be a relatively easy hurdle for Aura to clear.

2) MelaFind's intended use is restricted to lesions with signs of melanoma but it is not indicated for detection of non-melanoma skin cancers. Aura has demonstrated that it can detect both melanoma as well as non-melanoma skin cancers such as basal cell carcinoma and squamous cell carinoma. Non-melanoma skin cancer represent approximately 96% of all skin cancer cases (and cause ~ 25% of skin cancer related deaths) - if Aura can gain an indicated use for non-melanoma skin cancers, it's target market would be extraordinarily larger than MelaFind's.

We cover Verisante Technology (V.VRS - Analyst Report) with an Outperform rating and recently increased our price target from $2.25 to $2.60. As noted, we view this morning's news as an overall positive event for Verisante and are maintaining both our Outperform rating and $2.60 price target.

http://www.zacks.com/stock/news/61701/MelaFind+Approval+Is+P…

[M@trix]

Auch daher wird die Früherkennung mit maximaler Prognosesicherheit immer wichtiger:

Report: Cost of Cancer Is Becoming Unaffordable

"Other factors that increase costs in wealthy countries include overuse of unnecessary tests and the use of expensive diagnostic equipment. Overhauls of patient treatment models and health-care reimbursement models that affect doctors' incentives for using certain treatments or diagnostics are necessary, the panel said."

http://healthland.time.com/2011/09/26/report-cost-of-cancer-…

[M@trix]

Here we go... Aktuell +21%


Verisante Issues Update on Regulatory Milestones
10/6/2011 10:00:05 AM - Market Wire

Files With Health Canada and Readies Application for CE Mark

VANCOUVER, BRITISH COLUMBIA, Oct 6, 2011 (Marketwire via COMTEX News Network) --

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(PINK SHEETS:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that it has filed an application with Health Canada for a Class II Medical Device License to market and sell Verisante Aura(TM), a non-invasive medical device for the detection of skin cancer, in Canada.

The Company has completed all applicable safety testing required under Health Canada guidelines. Additional safety testing is also being done to confirm compliance with European guidelines. This additional testing is required to complete the Technical File for submission to a notified body to receive CE Mark approval for Europe. Verisante anticipates submitting our Technical File in October.

"We have come a long way and have met many milestones since licensing this technology from the BC Cancer Agency only 15 months ago," said President and CEO Thomas Braun. "As we move into the final quarter of 2011, we remain confident we will be able to meet our regulatory milestones of Canadian, European, and Australian approval by the end of the year."

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians' immediate results for many of the most common cancers. The Core(TM) has not yet been approved for sale.

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

http://www.verisante.com/news/66/verisante-issues-update-on-…

[M@trix]

Cantech Letter interviews Thomas Braun of Verisante Technology

http://www.cantechletter.com/2011/10/cantech-letter-intervie…


Highlights:

- We have raised a total of $8.7 million, which gives us a strong financial position.

- In fact, the key to unlocking our business model is the approvals. The CE Mark gets you into 27 countries in Europe, and Australia. And Health Canada approval is very important. It gets you into Canada but many other countries will accept Health Canada approval without requiring any additional clinical studies. For example, Brazil will accept Health Canada approval.

- The device will come in around the $60,000 mark, and I have no doubt that doctors will be able to afford it. When you look at competing type devices, doctors are paying $80-$110,000 for a laser that does laser hair removal. They’re paying $90,000 for machines that do non-surgical liposuction. For a one hour treatment on one these machines, here in Vancouver, they`re charging between $1300-$1500. One thing that has become clear is that whatever I am thinking about they will charge, dermatologists are thinking of charging much more.

- Between now and mid-2012 we’ll be approved in Canada, well be approved in Europe and in Australia and Starfish will be in full production. We expect to have the regulatory approvals before the end of this year, if all goes well. We don’t anticipate having a lot of troubles with these approvals because the device comes from a government agency and was tested for six years. We will start pre-marketing by going to dermatology and medical device conferences and trade shows. A lot of people simply won’t buy it until they can get a live demonstration, we expect that by March we will have fully functioning models from Starfish that we can take to trade shows and demonstrate for delivery in June. We should be generating revenue starting in eight months. Before the end of this year we will have seven fully functioning prototypes that we will send out to leading clinics in Australia, the UK, to Cambridge, and in the United Sates. We’ll use this to collect tons of data and then use that data to try and get FDA approval.

[M@trix]

In Antizipation kommender News hat die Verisante-Aktie heute die 1 CAD-Marke übersprungen. More to come.

[M@trix]

Oh ha! Da kommt was!

Investment Industry Regulatory Organization of Canada - Trading Halt - Verisante Technology Inc. - VRS

Reason for Halt: Pending News

[M@trix]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Popeye82]

Vermerk mich hier nurmal kurz(habe keine Aktien).

Gruß
P.

[M@trix]

Hallo Popeye82,

noch keine Aktien? Noch sind sie günstig...

Es hatten sehr viele diese News antizipiert und offentlichtlich auf einen stärkeren Anstieg spekuliert. So wurde nun das Gegenteil draus, was ich gleich mal für einen Zukauf genutzt habe.

Mit besten Wünschen,

M@trix

[schniddelwutz]

Antwort auf Beitrag Nr.: 42.243.721 von M@trix am 21.10.11 18:46:44

24.10.2011

Verisante Technology Inc. – Milliardenpotential mit Krebsfrüherkennungs Scanner





Verisante Technology Inc. – Milliardenpotential mit Krebsfrüherkennungs Scanner - Zulassung erhalten!

* Kanadische Behörde erteilt die Zulassung für Verisante-Produkte
* Innovatives Scan System zur Früherkennung von Krebs
* Markteinführung in Kanada und Europa Anfang 2012
* TSX notiert und streng reguliert
* Sehr gut finanziert mit über 5 Mio. CAD Cash
* Verisante Technology Inc.: Symb.VRS (TSX) Kurs: 0,58 EUR Kursziel: 2,00 EUR

Hautkrebs ist die weitläufigste verbreitetet Form von Krebs. Zudem ist sind Hautkrebserkrankungen die am schnellsten wachsenden lebensgefährlichen Erkrankungen überhaupt. In den USA sind 50% der Bevölkerung über 65 Jahre in einer Form von Hautkrebs betroffen, zudem stirbt jede Stunde in den USA ein Patient in Folge von Hautkrebserkrankungen. Wird Hautkrebs in einem frühen Stadium erkannt, liegt die Überlebenswahrscheinlichkeit bei über 98%, bei später Diagnose reduziert sich die Wahrscheinlichkeit auf nur noch 15%. Alleine die jährlichen Behandlungskosten nur in den USA liegen bei über 2,5 Mrd. US Dollar, wobei die Behandlungskosten im späteren Stadium 20 mal höher sind, als eine Behandlung nach frühzeitiger Erkennung.

Verisante Technologie Inc. Frühdiagnosesystem zur Krebserkennung mit weltweitem Mrd. Absatzpotential

Versisante Technolgies ist eine Medizin Technologie Firma, die das Versisante Hautkrebsfrüherkennungssystem ab 2011 weltweit vermarkten wird.

Mit Verisante TM Aura und Verisante TM Core hat die Gesellschaft zwei weltweit gültige Patente. In Zusammenarbeit mit der Krebsdiagnostikabteilung der Universität von British Columbia wurde die Technologie bereits erfolgreich an über 1000 Patienten getestet.

Das wissenschaftliche Team von Verisante hat zudem in den letzten Jahren zahlreiche Auszeichnungen im Bereich Krebsheilung bekommen. Versiante verfügt über ein weltweit führendes Team im Bereich der Krebs Früherkennung.

Hierzu gehören u.a. Prof. Dr. Harvaey Lui, Chef der dermatologischen Abteilung der University of BC, Prof Dr. David Mc Lean, President des Krebsfrüherkennungsteams von Kanada. Sowie Prof. Dr. Stephan Lam, Chef der Lungenkrebsabteilung der Universität von BC.In den letzten Jahren wurde zum einen der notwendige Scanner sowie die erforderliche Software weiterentwickelt, um im Jahr 2011 die Marktreife zu erlangen.

Kommerzialisierung des Verisante Früherkennungssystems - Verisante erhält Zulassung In Kanada

In der letzten Woche hat die Kanadische Behörde die Zulassung für die Verisante Krebserkennung genehmigt. Der Vetrieb der Produkte und der Erlös von Umsätzen kann nun sofort beginnen. Im Anschluss wird nun mit einer schnellen Zulassung auch in Europa gerechnet und in absehbarer Zeit auch in den USA. In den nächsten Monaten arbeitet das Management daran, die behördlichen Genehmigungen für den offiziellen Vertrieb in Kanada zu bekommen. Im Anschluss daran wird man die Märkte in Europa und USA angehen und dort die entsprechenden Genehmigungen zum Vertrieb beantragen. Die Serienproduktion sollte im Frühjahr 2012 beginnen, womit dann wohl auch die ersten nennenswerten Umsätze erwirtschaftet werden. Bereits im Jahr 2013 rechnet Zacks Equity Research mit Erlösen deutlich über der 10 Mio. Dollar Marke und dem Erreichen der Profitabilität.

Fazit:

Nach unserer Erstvorstellung am 10 Juni bei 0,56 CAD legte Verisante einen Zwischenspurt bis auf über 1 Dollar bei extrem hohen Umsätzen hin. In den letzten Wochen ist der Kurs wieder auf ein interessantes Einstiegsniveau zurückgekommen. Zudem wurde in den letzten Tagen die Vertriebszulassung durch die kanadische Gesundheitsbehörde erteilt. Zulassungen in Europa und den USA werden aller Voraussicht in Kürze folgen.

Verisante Technologie hat mit dem System zur Frühdiagnose von Krebs das Potential, einen Blockbuster am Markt zu etablieren! Die Gesellschaft ist mit 5 Mio. Dollar Cash gut finanziert und sollte bereits Anfang 2012 die ersten Umsatzerlöse erwirtschaften. Bereits im Jahr 2012 rechnet Zacks Equity Research mit Umsätzen von ca. 3 Mio. Dollar und in 2013 mit Umsätzen von ca. 17 Mio. Dollar und einem Gewinn von 7 Cent pro Aktie. Im Vergleich zu herkömmlichen Medikamenten ist das Zulassungsverfahren, um eine behördliche Vertriebsgenehmigung zu erhalten, um ein vielfaches schneller. Somit kann auch damit gerechnet werden, dass der internationale Roll Out des Produktes bereits im Jahr 2012 beginnt. Das weltweite Absatzpotential liegt bei einigen 100 Mio. Dollar pro Jahr, wobei eine extrem hohe Umsatzrendite erwirtschaftet werden kann. Im Peergroupvergleich ist Verisante zudem schon im jetzigen Status mindestens um den Faktor 3-5 unterbewertet. Die Aktie könnte sich in den nächsten Jahren durchaus zu einem Tenbagger entwickeln. Auf dem aktuellen Niveau von 0,60 EUR sehen wir auf Sicht von 12 Monaten ein Kursziel von 2,00 EUR

Verisante Technology Inc.: Symbol: VRS (TSX) A1JFNF, Kurs: 0,58 EUR Kursziel: 2,00 EUR

vom 24. 10.2011

[M@trix]

@schniddelwutz
Willkommen! Damit nimmt der Monolog ein Ende.

Hier mal wieder ein Artikel über Verisantes "Aura":

Verisante Aura Helps Automatically Spot Cancerous Lesions



Detecting skin cancer typically requires a dermatologist with a keen eye and a good deal of experience to identify the cancerous nature of skin lesions.34rr34risw5 Verisante Aura Helps Automatically Spot Cancerous Lesions A new device developed by the British Columbia Cancer Agency and the University of British Columbia Faculty of Medicine has just received Health Canada approval to help in early detection of skin cancer. The Aura, commercialized by local spin-off firm Verisante, does not require a dermatologist to operate and can be used by a clinical technician to provide an initial analysis. The Aura not only promises to help spot cancerous lesions early, it may help shorten waiting times and get more patients to receive screenings. Verisante is also reporting that it is shortly expecting European clearance of the Aura.

More about the Aura from the press release:

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system designed as a tool to aid medical professionals in the assessment of suspect skin lesions for diagnosis as either skin cancer or a benign disorder in less than two seconds.

Verisante Aura™ is a non-invasive device that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

http://medgadget.com/2011/10/verisante-aura-helps-automatica…

[schniddelwutz]

Antwort auf Beitrag Nr.: 42.255.931 von M@trix am 25.10.11 17:16:01

na ja, bis zum kz von 2 € wirds doch wohl noch ein bißchen dauern, aber,wer weiß.

[M@trix]

Verisante's (TSX.V: VRS) Aura™ has ability to revolutionize the way skin cancer is diagnosed

October 26, 2011 - Investorideas.com, a leader in sector research for independent investors issues an investor snapshot for TSX biotech stock, Verisante (TSX-V: VRS) following its October 19 th news, receiving Health Canada's approval for their innovative skin cancer detection device. The stock immediately moved up to over $1.00 on significant volume once the news was disseminated.

Verisante Technology, Inc Key Facts:

Revolutionary, patent-protected, platform technology!

- Applicable to several forms of cancer
- Clear regulatory pathway that will result in significant early revenue
- Imaging device for the safe detection of skin cancer now approved for sale in Canada
- Strategic alliances with leading institutions
- World class scientific capability
- Project management led by experienced, award-winning pioneers
- Medical and technical team led by renowned experts
- Highly qualified management, and Strong, independent board
- Raised $8.7 million in 2011, ensuring sufficient funding through commercialization

http://www.investorideas.com/news/2011/main/10261.asp

[schniddelwutz]

Antwort auf Beitrag Nr.: 42.263.935 von M@trix am 27.10.11 08:54:37

alle meldungen, die jetzt kommen interessieren anscheinend niemanden,da momentan andere probleme den ton angeben.aktuelle wirtschaftslage, bankenkrise, etc.etc. da kann ich nur sagen-stay long-die zeiten werden sich wieder ändern. außerdem sind wir noch etwas von 0,50 can$ tiefkurs entfernt.

[M@trix]

Gestern habe ich abermals zugekauft - sieht man ja am Volumen in Frankfurt... In Kürze startet ein sehr positiver Newsflow, der die Aktie nachhaltig über 1 CAD bringen sollte.

Etwas Lektüre:

Skin cancer tool replaces biopsy

Fall is not a time when many Canadians are worrying about skin cancer. But Verisante Technology Inc. of Richmond, B.C., had reason to celebrate recently when its Verisante Aura, a device that detects melanoma and other cancers in a quick and non-invasive way, was approved for sale by Health Canada.

"This is a defining milestone for our company," president and CEO Thomas Braun said in a release. The Aura uses an optical technology, Raman spectroscopy, to biochemically analyze the skin, providing immediate results. It not only spots melanoma but also basal cell and squamous cell skin cancers. Together they represent 96% of all skin cancer cases.

Right now such cancers are usually confirmed by way of a biopsy—a doctor literally removes tissue and sends it to a lab for analysis, which can take days. The Aura can be used by anyone trained to use it, and it can scan large numbers of lesions quickly. The cost of treating skin cancer exceeds half a billion dollars a year in Canada, so there's an opportunity for significant cost and time savings.

In a 2008 test at Vancouver General Hospital, the Aura caught all 34 cancerous lesions out of 274 tested and later confirmed by biopsy. The technology was developed by dermatologists at the B.C. Cancer Agency, which is due to receive a $120,000 milestone payment as a result of the Health Canada approval. TSX Venture-listed Verisante is aiming for Australian and EU approval next, followed by the U.S. Food and Drug Administration. The company is also working on an imaging device for early detection of lung, colon and cervical cancer.

http://www.canadianbusiness.com/blog/business_briefings/5495…

[D_Rockford]

Trading Halt

http://www.marketwire.com/press-release/iiroc-halt-verisante…

[M@trix]

Here we go.

CE Mark for Verisante Aura(TM) Opens Doors to Massive European Market
BY Market Wire

— 9:57 AM ET 11/09/2011

VANCOUVER, BRITISH COLUMBIA -- (MARKETWIRE) -- 11/09/11 -- Verisante Technology, Inc. (VRSEF) (FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that it has received notification of conformity to the European Medical Device Directive, allowing sales of Verisante Aura™ in Europe.

"Obtaining a CE Mark allows us access to a market of over 21,000 dermatologists and 500 million people," said Verisante (VRSEF) President and CEOThomas Braun. "2011 has been a breakthrough year for Verisante (VRSEF). With Canadian and now European approval, the Company continues to meet all of our commercialization milestones for Verisante Aura™ as we move closer to bringing this innovative, life-saving technology to market."

The Conformite Europeenne (CE) Mark approval is recognized by all the 27 Member States of the EU and by Australia through a reciprocity agreement. Verisante (VRSEF) intends its initial launch in the EU to begin in Germany, Austria and Switzerland, where distribution channels will be placed to support sales and marketing efforts.

The European medical device market is the second largest in the world, worth over $78 billion and representing 30 per cent of the world market -- second only to the United States. Within the EU, the largest markets are Germany, UK, France, Italy, and Spain. These five countries make up 60 per cent of the total EU population, account for more than 70 per cent of the total EU GDP, and approximately 80 per cent of the EU medical device market. With an aging population and several new members in central Europe, the EU medical market continues to grow. One of its fastest-growing segments is the field of cancer diagnosis and treatments.

In Germany the incidence of skin cancers has tripled since 1980 and is about 20 per cent higher than the rest of Europe, with melanoma accounting for 2,217 deaths each year. With a population of 80 million, Germany also offers a reimbursement of 150 Euro under their state health insurance which covers skin cancer screenings every two years for people age 35 and older.

"Verisante Aura™ is a unique tool that can assist doctors in the efficient diagnosis of skin cancers," said Dr.Harvey Lui, MD, FRCPC, Director of the Skin Care Centre at Vancouver General Hospital, Dermatologic Oncologist at the BC Cancer Agency, Professor and Head, Department of Dermatology and Skin Science, University of British Columbia, and one of the inventors of the Aura™.

"With the rising incidence of all types of skin cancers, innovative tools such as the Aura™, which can potentially be used by general practitioners to evaluate suspicious skin lesions quickly and accurately, will become increasingly important to the heathcare system," said Dr. Lui.

The study used to support the CE Mark application was a six year clinical study completed at the Skin Care Centre at Vancouver General Hospital, where Verisante Aura™ was used to collect data on over 1,000 lesions.

Early detection is key to saving the lives of melanoma patients and saving healthcare costs. When melanoma is diagnosed and treated in the earliest stages, the survival rate is 99 per cent and it costs about $1,800 to treat it. In the late stages, the survival rate decreases to 15 per cent, while the cost to treat it increases to $170,000.

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96 per cent of all skin cancers. While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best results for patients.

Aura™ is a non-invasive optical system designed as a tool to aid medical professionals in the assessment of suspect skin lesions for diagnosis as either skin cancer or a benign disorder in less than two seconds. The device uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The Aura™ will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

The Company will also now register Aura™ with the Therapeutics Goods Administration in Australia.

About Verisante Technology, Inc. (VRSEF)

Verisante (VRSEF) is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante (VRSEF) to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Core™ has not yet been approved for sale.

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Verisante Technology, Inc. (VRSEF)

Thomas Braun

President & CEO

[phone]

[e-mail]

www.verisante.com

[M@trix]

Schöne Präsentation:

http://www.scribd.com/doc/70859522/Verisante-Technology-Inc

Interessant wäre, wie viele Optionsscheine bereits ausgeübt wurden. Ich nehme an, da liegt der Grund für die regelmäßigen "Sell the news".

Ungeachtet dessen bleibt das Unternehmen auf Kurs. 2012 wird ein spannendes Jahr!

Doch nun geht es erst mal zur Medica.

[Donn]

Antwort auf Beitrag Nr.: 42.331.487 von M@trix am 10.11.11 14:41:51

4.593 Firmen... da hast eine Menge Arbeit vor dir... viel Vergnügen...

Gruß
Donn

[M@trix]

Popular Science Honors Innovative Verisante Aura™ Skin Cancer Detection Device with “Best of What’s New” Award

November 16, 2011 at 9:00 am

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that the editors of Popular Science magazine have named Verisante’s Aura™ device for skin cancer detection as a top technology innovation of 2011, receiving one of the magazine’s coveted “Best of What’s New” Awards.

“For 24 years, Popular Science has honored the innovations that surprise and amaze us − those that make a positive impact on our world today and challenge our views of what’s possible in the future,” said Mark Jannot, Editor-in-Chief of Popular Science. “The Best of What’s New Award is the magazine’s top honor, and the 100 winners − chosen from among thousands of entrants − represent the highest level of achievement in their fields.”
Thomas Braun, President and CEO of Verisante Technology, Inc., said Verisante is honored to be recognized by Popular Science as a company that is making revolutionary advancements in the detection of skin cancer.

“This award is a validation of the hard work and dedication of our employees, consultants, and partners who have come together to make the commercialization of this life-saving device possible,” he said. “We are pleased that our commitment to innovation and the exceptional work done by the BC Cancer Agency to develop the Verisante Aura™ is being internationally recognized.”

Early detection is key to saving the lives of melanoma patients and saving healthcare costs. When melanoma is diagnosed and treated in the earliest stages, the survival rate is 99 per cent and it costs about $1,800 to treat it. In the late stages, the survival rate decreases to 15 per cent, while the cost to treat it increases to $170,000. The Aura™ will aid medical professionals in the assessment of suspect skin lesions for diagnosis as either skin cancer or a benign disorder in less than two seconds.

Verisante Aura™, a non-invasive optical system, is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. 

The Popular Science issue containing the winners of the Best of What’s New Awards is now on sale. 

About Best of What’s New

Each year, the editors of Popular Science review thousands of products in search of the top 100 tech innovations of the year; breakthrough products and technologies that represent a significant leap in their categories. The winners – the Best of What's New – are awarded inclusion in the much anticipated 
December issue of Popular Science, the most widely read issue of the year since the debut of Best of What’s New in 1987. Best of What’s New Awards are presented to 100 new products and technologies in 11 categories.
About Popular Science

Founded in 1872, Popular Science is the world’s largest science and technology magazine; with a circulation of 1.3 million and 6.8 million monthly readers. Each month, Popular Science reports on the intersection of science and everyday life, with an eye toward what’s new and why it matters.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to
develop and offer a range of compact, non-invasive cancer detection devices that offer physicians’ immediate results for many of the most common cancers. The Core™ has not yet been approved for sale.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:
Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: [phone]
Email: [e-mail]
Website: www.verisante.com
Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

[M@trix]

Verisante Technology: The Future Of Cancer Detection

http://seekingalpha.com/article/309265-verisante-technology-…

[M@trix]

VERISANTE Technologies: introducing a new CORE position for the Innovation Fund

"In fact, Verisante has moved from “farm team” to core faster than any other position in the history of the fund [...].

Either way, Verisante is a largely de-risked medical device story which should generate excellent returns for my investors over the next 2-3 years; longer-term, this could be a $5-$10 stock."

http://www.northernriversfunds.com/assets/downloads/Cleland%…

[M@trix]

Ebenfalls sehr spannend:

Multispectral LEDs shed light on oral cancer

December 15, 2011 -- Multispectral imaging has long been used for space-based analysis of environmental conditions, crop management, and urban growth. Can this same advanced technology improve the ability to detect oral and skin cancers?

A Canadian medical device company with roots in terahertz imaging thinks so. Verisante Technology -- a public company formerly known as T-Ray Science -- has licensed multispectral imaging technology developed by researchers from the British Columbia Cancer Agency (BCCA) and is now developing a prototype for clinical testing in the detection of oral and skin cancers.

Verisante's goal is to create a low-cost, user-friendly device that can identify cancerous lesions in the epithelial layer of tissue with more sensitivity and specificity than existing cancer detection methods.

"It will be like a digital camera with LEDs [light-emitting diodes] of different wavelengths that will take measurements from the reflected light and analyze the spectral fingerprint to give the practitioner an on-the-spot answer on whether they are looking at a high- or low-risk lesion and whether or not they should do a biopsy," said Thomas Braun, CEO of Verisante. "This technology is designed to raise specificity so you don't get as many false positives."

The system will use LEDs operating in several wavelengths to measure changes in the scattering properties of tissue and thus detect suspicious cellular changes, according to Haishan Zeng, PhD, a senior scientist in the BCCA's Integrative Oncology Department and co-inventor of the technology.

"Multispectral imaging is reflectance-based, so what you are getting is information about chromophores in the tissue," Zeng said. "The goal for us is to help identify suspicious lesions and to determine which lesions to biopsy and which location in the lesions to biopsy."

Attractive price point

In the past year Verisante has acquired the rights to two dozen patents and patents pending for cancer detection technologies, including white light reflectance imaging, fluorescence imaging, rapid Raman spectroscopy, and rapid multispectral imaging. The company's flagship product is a rapid Raman imaging system for detecting skin cancer that could also be used in the oral cavity.

While the Raman technology offers advantages over multispectral imaging in terms of sensitivity and specificity, it is also more expensive, which could make it a tougher sell in the dental market, according to Braun.

"The Raman system is expected to retail for $60,000," he said. "The trouble with developing a Raman dental probe and then doing a clinical study and getting all the regulatory approvals is that the only people who are willing to pay $60,000 are major medical centers."

The price point for the multispectral device is expected to be less than $5,000, he noted.

"The ideal would be to combine the multispectral and Raman imaging devices, but not everyone can afford the Raman system," Zeng said. "And in a lot of cases, multispectral can be quite good and very useful."

Zeng is now working with Verisante on the multispectral prototype.

"What we are trying to do is build a better, cheaper, more reliable instrument, with better ways to gather data," Zeng said. "We are developing physical modeling to extract the information from the image data."

Once the prototype is ready, Verisante will conduct a clinical trial, apply for Health Canada approval, obtain the European CE Mark, and then approach the U.S. Food and Drug Administration to file for 510(k) clearance, according to Braun. The company is already certified by the International Organization for Standardization (ISO) as a medical device manufacturer, he noted.

Another multispectral device

Verisante is not alone in its belief that multispectral imaging has a place in oral cancer detection. The Identafi oral cancer screening device -- originally developed by Trimira but acquired earlier this year by DentalEZ -- uses a combination of white, violet, and green-amber multispectral wavelengths to detect biochemical and morphological changes in the cells of the mouth, throat, tongue, and tonsils that may potentially lead to oral cancer.

Identafi is intended for use by dentists, hygienists, and oral surgeons and sells for about $3,200. An insurance code exists for the screening procedure, according to DentalEZ, and about 40% of insurers are currently reimbursing for this procedure.

But Braun believes the Verisante device will be a "quantum leap" forward from the Identafi and other commercially available cancer screening and detection products.

"What we are trying to do is come up with something that yields spectroscopic quality at a much lower price," he said. "A lot of medical devices can cause anxiety for the patient, but we want these products to be approachable. Ultimately, we want to be the Apple of medical devices."

http://www.drbicuspid.com/index.aspx?sec=sup&sub=img&pag=dis…


Wer die Aktie bislang nur auf der Watchlist hat, sollte nun ein Investment in Bertracht ziehen. Der Verkaufsdruck durch auslaufende Warrants sowie Tax Loss Selling dürfte in Kürze enden.

[M@trix]

Und wieder liefert das Management "in time". Klasse!

Verisante Obtains Australian Approval

Verisante Aura receives ARTG listing by the therapeutic goods administration of Australia

VANCOUVER, BRITISH COLUMBIA--(Marketwire -12/19/11)- Verisante Technology, Inc. (TSX-V: VRS.V - News)(OTCQX: VRSEF.PK - News)(Pinksheets: VRSEF.PK - News)(Frankfurt: V3T.F - News) (the "Company" or "Verisante"), a leader in skin cancer detection technology, announced today that it has received regulatory approval to market and sell the Verisante Aura in Australia.

"After Canadian and European approval earlier this quarter, obtaining Australian approval completes the Company's regulatory goals for 2011," said Thomas Braun, President and CEO. "In Australia, access to quick, accurate information to aid skin cancer diagnoses is absolutely essential."

According to the Australian Government Department of Health, Australia has the highest skin cancer incidence rate in the world, at nearly four times the rates in Canada, the US and the UK. And thirteen times the global average. Australians are also four times more likely to develop a skin cancer than any other form of cancer, and approximately two in three Australians will be diagnosed with skin cancer before the age of 70.

Furthermore, general practitioners (GP) in Australia have more than 1 million patient consultations per year for skin cancer. GP consultations to treat non-melanoma skin cancer increased by 14% between 1998-2000 and 2005-2007 - from around 836,500 to 950,000 visits each year, or more than 2,000 skin cancer patient visits per day.

Verisante Aura is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96 per cent of all skin cancers. While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best results for patients.

Aura™ is a non-invasive optical system designed as a tool to aid medical professionals in the assessment of suspect skin lesions for diagnosis as either skin cancer or a benign disorder in less than two seconds. The device uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The Aura™ will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Core™ has not yet been approved for sale.

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Contact:

Verisante Technology, Inc.
Thomas Braun
President & CEO
[phone]
[e-mail]
www.verisante.com

http://finance.yahoo.com/news/Verisante-Obtains-Australian-i…

[M@trix]

Verisante Starts FDA Approval Process and Provides Operational Update

December 22, 2011 at 7:00 am

2011 A BREAKTHROUGH YEAR FOR VERISANTE AURA

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in skin cancer detection technology, has begun the process to obtain US Food and Drug Administration (FDA) approval for Verisante Aura. Verisante expects to have a pre-Investigational Device Exemption meeting with the FDA in the first quarter of 2012 to receive regulatory guidance.

“The Company has reached all of our major milestones this year,” said Thomas Braun, Verisante President and CEO. “In addition to obtaining Health Canada and European approval for Verisante Aura, we have been able to garner significant media attention and industry awareness of our innovative products. Being a recipient of Popular Science magazine’s Best of What’s New award was a great endorsement of the Aura’s breakthrough technology.”

A summary of significant corporate highlights and achievements for 2011 include:

A name change and rebranding of the Company, including a new logo and website
Research coverage initiated by Zacks Investment
Raising $6 million in private placement financings
Raising an additional $3.2 million through the exercise of stock options and warrants
Current cash balance of approximately $6 million
Obtained listings on the OTCQX and Frankfurt Stock Exchanges
Announced pilot study results for lung cancer detection system using the Verisante Core. 
The study demonstrated 96% sensitivity and 91% specificity, which set a new standard for lung cancer detection.
Purchased 17 cancer imaging patents and the ClearVu and ClearVu Elite assets from Perceptronix Medical and in-licensing multispectral imaging technology developed by the BC Cancer Agency
Completed industrial design of Verisante Aura and engaged a contract manufacturer
Awarded ISO 13485:2003 certification as a medical device developer and manufacturer
Awarded Health Canada approval for the Aura
Awarded CE Mark for the Aura
Featured by more than a dozen major media outlets, including CNN and the National Post. All media coverage can be found on the Company’s website.
Verisante Aura awarded Best of What’s New Award by Popular Science magazine
Received Australian registration for the Aura

The academic paper on the statistical analysis completed by the University of British Columbia earlier this year is now awaiting acceptance for publication. Verisante will announce the results of the analysis once authorized to do so.

The Company has also increased the number of initial production units from 7 to 10, and Verisante is now completing the testing of the units. These initial devices will be used in field testing sites and post-market studies.

The Company has begun pre-marketing the Aura by exhibiting at various dermatology conferences. Verisante Aura will go into production and sales in the second half of 2012. The Company is currently selecting distributors and will first launch the Aura in Canada, Germany, Austria, Switzerland and Australia.

“There are 21,000 dermatologists in Europe and 5,500 dermatologists in Germany, which we think will be the most significant market in Europe,” said Braun. “While we seek FDA approval, our CE Mark and Health Canada approval allow us to build our revenue in these other markets.”

Health Canada also approval clears the way for the Company to register Verisante Aura for sale in Mexico and Brazil. Verisante has begun the registration process for these countries and expects to obtain Mexican registration in 2012 and Brazilian registration in 24 months.

Australia has one million consultations per year for skin cancer and Brazil has one of the highest rates of skin cancer in the world and a population of 193 million people.

“We now have access to markets where quick, accurate information to aid skin cancer diagnoses is absolutely essential,” said Braun. “Early detection of skin cancer saves lives and saves dollars, making the Verisante Aura a compelling device for healthcare professionals and their patients.”

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Core™ has not yet been approved for sale.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: [phone]
Email: [e-mail]

Website: www.verisante.com
Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante


In der Tat beeindruckend!

[M@trix]

Verisante Aura set to revolutionize early skin cancer detection

"If you happen to think that Verisante’s next round of information releases, expected “in January and February”, will be really pivotal, you could always take a small flier now — you can place a cheap bet on Verisante Technology. And I wouldn’t even call it an aggressive gamble, for if they end up calling this the next Intuitive Surgical, when shares double or quadruple (or, in a lightning strike, go up 1,000%), you’d take in a mighty profit with a very limited risk.

And on another positive note: we’re talking about medical devices here, not drugs, so the approval timeline for the FDA process will be shorter.
Oh yeah, I forgot to mention that the FDA has already agreed to meet with Verisante management for a pre-Investigational Device Exemption conference in Q1 2012. So this company, though tiny, is not just raw science and faint hope, they do have real products and genuine potential for sales once the devices roll-out happens in the second half of 2012. Maybe or maybe not profitable sales, but still, that is way more than what MELA Sciences Inc. has going for them.

Verisante Technology is a tiny, tiny company with a market cap of around $50 million, so be careful."

http://seekingalpha.com/instablog/1097393-dufferdud/247710-v…

[M@trix]

Canadian Cancer Society Names Verisante Core a Top 10 Cancer Breakthrough of 2011

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/09/12 -- Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT: V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that a research study using its Laser Raman Spectroscopy was named as one of the Canadian Cancer Society's 10 research achievements for 2011.

"2011 has been a very exciting year for cancer research," said the Canadian Cancer Society's Sarah Bouma. "Society funded researchers have made tremendous gains, particularly in clinical trials. Research advances across the country are impacting the lives of people living with cancer, their families and caregivers."

In July 2011, Verisante announced the results of a pilot study on lung cancer detection led by Dr. Stephen Lam and Dr. Haishan Zeng and conducted at the Lung Centre at Vancouver General Hospital. Results were published in the Journal of Thoracic Oncology. The study, funded by the Canadian Cancer Society, used the Verisante Core's Laser Raman Spectroscopy System, which was able to detect pre-cancerous lung lesions with 96 percent sensitivity and 91 percent specificity when used in combination with existing methods. The application of the Core could improve early detection of lung cancer and reduce the number of false positives associated with other methods.

The Canadian Cancer Society's recognition comes soon after editors of Popular Science magazine named Verisante's Aura(TM) device for skin cancer detection as a top technology innovation of 2011, receiving one of the magazine's coveted "Best of What's New" Awards.

"The recent accolades from the Society and Popular Science for Verisante technologies reflects our commitment to helping healthcare providers save lives through the early detection of some of the common forms of cancer," said Thomas Braun, Verisante President and CEO.

For further information, please see the Canadian Cancer Society's media release and Top 10 Breakthrough fact sheet.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
[phone]
[e-mail]
www.verisante.com


Die monatelange Konsolidierung sollte bald ihr Ende finden. Heute ein schönes Plus bei überdurchschnittlichem Volumen.

[Dr.Reuter [IR/PR]]

Liebe Verisante-Interessierte,

gern möchten wir am Donnerstag den 26.01.2012 um 19 Uhr (CET) zu einer kostenlosen Web-Konferenz mit Herrn Thomas Braun einladen.
Wie in der Vergangenheit ist die Konferenz kostenlos und zweisprachig. Des Weiteren ist wie üblich eine anonyme Teilnahme möglich.


Fragen und Anregungen sind per Chat möglich.

Hier der Teilnehmerlink:

https://eu42.spreed.com/checkin/jc/621476961


Weitersagen ausdrücklich erwünscht.


Mit freundlichen Grüßen,
Eva Reuter

[Ahorne]

*lesezeichen*

[schniddelwutz]

Zitat von Ahorne: *lesezeichen*

du sagst es, aber langsam wird der chart interessant

[Ahorne]

Ich habe eine Frage:

Inwiefern ist ist Manhattan Scientifics eine Konkurenz für Verisante Technology?

Eien Antwort wäre Klasse

lg. A

http://www.mhtx.com/investors.htm
Manhattan Scientifics acquired the exclusive commercial rights (manufacturing and marketing) to Edward R. Flynn's (president and CEO of Senior Scientific, LLC) patents and IP in the emerging field of nano medicine; specifically Dr. Flynn's work in biomagnetic detection of cancer and other diseases through magnetic field sensors. These sensors make it possible to identify and image small clusters of cancer cells substantially increasing the sensitivity for finding cancer at an earlier stage than is currently available, and without the use of ionizing radiation or large magnetic fields. The biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate, melanoma, and other cancers. Dr. Flynn's research has been funded by the National Institute of Health (NIH). Management intends to identify one or more appropriate Fortune/500 industrial partners in the Big Pharma group to bring product to the market under royalty bearing licenses.

[M@trix]

Field Testing Ongoing / Rodman Presentation - Analyst Blog

"We continue to model an initial launch in late 2012 with an immaterial amount of revenue in the current year but showing a steep ramp throughout 2013. We had previously modeled Aura to launch in the U.S. in late 2014 but given the slight delay in the IDE process (initially an IDE meeting was expected earlier in 2012), we have pushed back our assumed U.S. launch of Aura from late 2014 to mid-to-late 2015 (slightly more conservative than management's late-2014 guidance, which provides some cushion for further delays). Updates to our model mostly effect years 2014 - 2015 with a much more muted impact over the longer-term.

As commercialization (ex-U.S.) is now expected to be a near-term event, we are now using DCF as our valuation methodology. Key inputs to our 10-year DCF model include a 10% discount rate and 2% terminal growth rate. Our DCF model values VRS at about $2.70/share (which is very much in-line with our prior valuation of $2.60/share)."

http://community.nasdaq.com/News/2012-09/field-testing-ongoi…

[M@trix]

Verisante Technology, Inc. Announces Exclusive Distribution Agreement with BO-Pharma BV for Benelux Region

Company to Attend 21st Congress of the European Academy of Dermatology in Prague, Czech Republic

"BO-Pharma is the largest independent distributor of medical devices in the Benelux region," said Thomas Braun, President & CEO of Verisante. "With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura(TM), but can also support technical training and servicing in the region."

http://finance.yahoo.com/news/verisante-technology-inc-annou…

[M@trix]

Verisante Provides Operational Update

December 20, 2012 at 7:00 am

2012 A FOUNDATION YEAR FOR THE INNOVATIVE, LIFE-SAVING SKIN CANCER DETECTOR AS IT READIES FOR MARKET LAUNCH

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, provides a year-end wrap up and operational update.

A summary of significant corporate highlights and recognition for 2012 include:


Canadian Cancer Society named Verisante Core™ a Top 10 Cancer Breakthrough
Verisante named the top Technology and Life Sciences Company by the TSX Venture Exchange on the TSX Venture Top 50 2012 ranking
Company signed an exclusive Canadian distribution agreement with Clarion Medical Technologies, the top distributor of dermatology devices in Canada with a large installed base and headquartered outside Toronto, Ontario
Cancer Research, a peer-reviewed journal of the American Association of Cancer Research, published Verisante Aura™ clinical study results
Study results conclusively demonstrated Aura’s™ diagnostic accuracy (very high sensitivity rate of 99 per cent in accurately differentiating all major skin cancers from benign lesions) and potential for reducing unnecessary biopsies by 50 to 100 per cent
Verisante was chosen Pick of the Street in the Technology Sector by leading fund managers, analysts, and retail brokers
Expanded and renovated engineering facility in Richmond by adding approximately 1500 square feet of production and assembly area for Aura™. Verisante now occupies over 5,000 square feet of office space in Metro Vancouver
Completed Beta Units and placed them for field testing in clinics across Canada in Vancouver, Calgary, Edmonton, Oakville, Markham and Montreal
Extended a Research Agreement with BC Cancer Agency to fund continued development of the Aura™ and for further research and development of the Core™
Took delivery of first two completed Aura™ pre-production units from StarFish Medical
Exhibited at, and attended several dermatological conferences around the world including the American Academy of Dermatology Annual Meeting in San Diego, the World Congress of MRTs in Toronto, and the European Academy of Dermatology and Venereology Congress in Prague where a working model of Aura™ was displayed
Signed an exclusive distribution agreement with Bo-Pharma/Bo-Aesthetics (the largest independent distributor of leading brands of medical devices in Benelux) for the Benelux region, which together have 1,000 dermatologists
Took delivery of final pre-production unit from StarFish Medical
Completed technical and operational training with distribution partner
Verisante Aura™ named a finalist for the 2013 SPIE Prism Award
Intermediate clinical study results on lung cancer presented at the annual BC Cancer Agency Research Conference demonstrated that Verisante Core™ is best in class for lung cancer detection
Verisante Aura™ early prototype currently being exhibited at the Canada Science and Technology Museum in Ottawa and accepted into the museum’s permanent collection

“2012 has been a year of foundation building and growth for Verisante,” said Thomas Braun, President & CEO. “We have successfully achieved our goals for this year and laid the groundwork for a full product launch of Verisante Aura™ in 2013 as we complete transfer to manufacturing processes this year. Our distribution partners are highly motivated and excited and we continue to work closely with them on sales and marketing support.”

The Company is finalizing the design of marketing and sales brochures, in addition to packaging solutions for Aura’s™ clean tips. Aura™ is a revolutionary device which has been developed with safety and ease of use as core principals embedded into a functional and attractive industrial design. The disposables will ensure the integrity of the system and safety for the patient. Combined with our user friendly touch screen and graphical user interface, both doctors and patients can look forward to taking advantage of this ground breaking technology as we move into production this year for delivery and full product launch in 2013. Visit Verisante’s Facebook page at www.facebook.com/verisante for an early sneak peek of some of the packaging.

The Company now has 22 full-time and part-time employees and consultants working directly on Verisante’s products, including Aura™, Core™ and other pipeline projects; in addition to dozens of contract manufacturers who have been qualified as parts and fulfillment suppliers and service providers.

http://www.verisante.com/news/92/verisante-provides-operatio…

[M@trix]

Fast 1 Jahr später un nach einem dramatischen Kursverfall deutet sich heute eine Wende an. Dazu auch lesenswert:

"Since inception we have raised over $18 million in capital and we will continue to raise funding in the capital markets as required, but we are also reaching out to bigger companies to form strategic partnerships for non-dilutive financing. Most of the development work is already done and many of the clinical studies are funded by granting agencies in various countries. With so many clinical studies already done or in progress, and the numerous awards we have won including two in 2013, we feel that now is the right time to start the process of partnering with other companies to assist in the regulatory approval, marketing and distribution of our product pipeline. We have reached out to many companies and the conversations are just beginning. Because sometimes these strategic partnerships are the first step towards a complete takeover, I think any announcement in this area could be a major catalytic event for our stock."

http://www.cantechletter.com/2013/11/verisante-ceo-thomas-br…

[M@trix]

+50% - so kann es weitergehen! :-)

Kurs aktuell 0,34 CAD

Kursziele 1,05 CAD und 2,00 CAD:

SeeThruEquity (9/9/13) "We are initiating coverage on Verisante Technology Inc. with a fair value of $1.05/share. . .with the initiation of sales in Canada and new distribution agreements in Europe, we see sales of Aura quickly escalating over the next few quarters. . .once the results of the current study are peer tested and published, we expect that the company will be able to seek and obtain regulatory approval for Core's lung cancer application."

http://www.thelifesciencesreport.com/pub/co/4715

"We use 10-yr DCF to value VRS. Key inputs to our 10-year DCF model include a 10% discount rate and 2% terminal growth rate. Our DCF model values VRS at about $2.00/share."

http://verisante.com/docs/verisante_zacks_Dec2013.pdf


Zuletzt gigantische Umsätze in der Aktie:



2014 sollten wir Richtung Allzeithoch laufen.

[M@trix]

Der Anstieg wurde um 50% korrigiert. Jetzt sollte sich der Wert fangen und seitwärts/aufwärts tendieren, bis wieder relevante News kommen, was vermutlich erst Ende Januar/Anfang Februar der Fall sein wird.

[M@trix]

Lesenswert - es zeigt Pro und Contra und lässt erahnen, dass Aura nicht so schnell "der Hit" werden wird, obwohl die Technologie sehr gut ist:

Shedding a light on skin cancer

B.C.-invented Aura is ready for prime time, but will medicare pay?

http://www.vancouversun.com/health/Shedding+light+skin+cance…

M.E. ist es nicht "Aura", sondern "Core", das den wirtschaftlichen Erfolg bringen wird. Indes wird dies noch eine Weile dauern...

[Popeye82]

ich habe die Aktie nicht.

Verisante Technology, Inc. Announces Milestone Completion of Core™ Commercial Prototype for the Detection of Lung Cancer, Completes Recertification of ISO Certificate of Quality Management System for Medical Device Manufacturing - May 13, 2014
www.marketwired.com/press-release/verisante-technology-inc-a…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 13, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has completed the development of the Core™ Series commercial prototype to aid in the detection of lung cancer.

The Core™ system, which is based on the same platform technology as Verisante's award winning Aura™ device for the detection of skin cancer, will be used to prepare for the Company's application for Regulatory Approval in Canada, Europe, USA and China for the lung cancer indication.

A clinical study on lung cancer using the Core™ technology has been completed and the Investigators of the study are currently preparing a paper for publication. Previously published results showed that the device can measure the difference between low grade and high grade dysplasia, as well as carcinoma in situ.

Core™, for lung cancer detection, employs an endoscopic probe that can be used in bronchoscopy procedures to help analyze lesions for malignancy. A bronchoscopy is normally performed by a doctor under local anaesthetic to look for abnormal tissue and to take tissue samples, (or biopsies) if necessary. The Core™ probe enters through the biopsy channel of the bronchoscope and measures the Raman spectra of the abnormal tissue, providing immediate feedback of the results of the spectral measurement to the doctor. The probe is an endoscopic accessory that will fit with all major brands of endoscopes. It will also be equipped with a consumable sheath to be discarded after each procedure.

In the United States, more than 500,000 bronchoscopies are performed annually to diagnose lung disease, and the American Cancer Society estimates the number of new cases of lung cancer diagnosed will be more than 224,000 in 2014.

In addition to the USA, Verisante anticipates one of the other major markets for Core™ for lung cancer will be China, where bronchoscopies are already widely performed. According to the World Health Organization's World Cancer Report 2014, 1.59 million people died from lung cancer globally in 2012, and China, with approximately 20 percent of the world's population, accounted for more than one third of those deaths.

Lung cancer is the leading cause of cancer related deaths worldwide in both men and women, and has recently surpassed heart disease as the leading cause of smoking-related mortality. More people die from lung cancer than breast cancer, colorectal cancer and prostate cancer combined.

Verisante also has exclusive worldwide rights to the Core™ technology for the detection of gastro-intestinal, colorectal and cervical cancers by utilizing the same hardware with different diagnostic algorithms. In addition, the Company has an option to license the exclusive rights for nasopharyngeal cancer. Clinical studies are currently underway for nasopharyngeal and colon cancers, with more studies in the planning stages.

"Seeing the Core™ device for lung cancer detection come to life is a major milestone for Verisante. We are now one step closer to getting this product in front of patients around the world." said Thomas Braun, President & CEO. "The purpose of the Core™ is to help save lives and save money for the health care system through assisting in the early detection of cancers and pre-cancers."

To view photos of Core™, visit the Company's facebook page at www.facebook.com/verisante

ISO Recertification of Quality Management System for Medical Device Manufacturing

The Company also announced today that it has successfully completed the re-certification process for ISO 13485:2003, an internationally recognized quality management standard. Verisante was originally ISO certified in 2011 and requires re-certification every three years. The re-certification is a confirmation of the Company's ability to design and manufacture medical devices.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[Popeye82]

Verisante Technology, Inc. Receives the '`14 North American Technology Innovation Leadership of the Year Award', from Frost & Sullivan - May 20, 2014
http://verisante.com/news/130/verisante-technology-inc-recei…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 20, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has been honoured by Frost & Sullivan with the 2014 North American Technology Innovation Leadership of the Year Award for In Vivo Cancer Detection for its product, Verisante Aura™, a device for the detection of skin cancer.

"Verisante is pleased to accept the recognition of Aura™ as an innovative and disruptive technology that can make a positive impact on healthcare outcomes for skin cancer patients," said Thomas Braun, President and CEO. "As more Aura™ units are placed in clinics we believe this innovative technology can become part of the standard of care for assisting doctors in monitoring and diagnosing skin cancer."

Frost & Sullivan follows a 10-step process to evaluate candidates and assess their fit with its best-practice criteria. Frost & Sullivan's global network of consultants and analysts are asked to monitor, target, analyze and screen creative practices within their regions and to confer with their industry peers. An independent board of advisors considers the findings in order to choose the company that excels in its industry above all others in customer value leadership. Based on its analysis of the in vivo cancer detection market, Frost & Sullivan recognized Verisante as the leader for its commitment to innovation and technology excellence.

"Aura™ has a unique competitive advantage in the marketplace as it is capable of providing almost instantaneous information about the biochemical nature of a skin lesion," notes Frost & Sullivan Industry Analyst, Darshana De. "This advantage, and the potential for the same technology to be used for the detection of lung, colon and cervical cancer, differentiates Verisante as a leader in technology innovation."

Frost & Sullivan has more than 50 years of experience in business and is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies.


About Frost & Sullivan

Frost & Sullivan enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. We leverage 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from over 40 offices on six continents.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[Popeye82]

Verisante Technology Inc. Announces Preliminary License Agreement with Astoria Capital, for Cancer Detection Technology - May 29, 2014
http://verisante.com/news/131/verisante-technology-inc-annou…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 29, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it has signed a letter of intent, subject to a final definitive agreement, with Astoria Capital SA (WAR:ACL) to sub-license and, in turn, finance the development and commercialization of Verisante's cancer detection technology for the upper gastrointestinal system ("Upper GI Instrument").

Under the letter of intent, Astoria and Verisante plan to form a Polish joint-stock company, Verisante Technology Europe S.A. ("VTE"). ACL will receive 70% of the total equity in VTE, and Verisante will receive 25% of the total equity in VTE for assistance in management and commercialization of the technology. 5% of the shares will be reserved for Management and Supervisory Board members appointed by Verisante.

Under the terms of the letter of intent, Verisante will sublicense to VTE the worldwide exclusive technology rights for the Upper GI Instrument. VTE will pay VRS a 3% royalty on instruments sold and VRS will act as the contract developer and manufacturer of devices for VTE. VTE will also pay VRS a development fee of $1 million upon regulatory approval of a device for the Upper GI in Europe.

In addition, VTE will provide financing for up to USD $2.5 million for development and commercialization of the Upper GI Instrument, including regulatory costs. VTE will apply for EU grant funding and plans to list on the Warsaw Stock Exchange at an agreed upon time before or after completing development of the instrument. ACL will be responsible for raising any additional equity capital required to support development and commercialization of the upper GI instrument.

Thomas Braun, President and CEO of Verisante Technology, stated, "We appreciate Astoria Capital's support in forming Verisante Technology Europe with us. This joint venture is a great opportunity to accelerate the development and commercialization of our early cancer detection technology for the upper GI tract. We look forward to further expanding our reach and exposure within the European capital markets."

Mr. Adrian Dzielnicki, Vice President of Astoria Capital S.A., commented, "Gastrointestinal cancer is extremely common and nearly impossible to diagnose at an early stage. Verisante's technology was developed by the BC Cancer Agency and has been proven in the early diagnosis of skin cancer. Their platform technology has a broad reach and vast potential, and we look forward to accelerating the development of the Upper GI Instrument."


About Raman Spectroscopy, in the Upper Gastrointestinal system

The Raman technology on which the Upper GI Instrument will be based was tested in preliminary clinical studies for esophageal and stomach cancer with encouraging results.

The Upper GI applications will includes everything from the esophagus to the stomach and duodenum. Using the Raman system will assist doctors in distinguishing between mild dysplasia, severe dysplasia and carcinoma in situ, which will greatly enhance patient outcomes by helping to detect lesions at the precancerous stages and could prove very useful to managing pre-malignant conditions such as Barrett's esophagus which may afflict up to 6 percent of the population in western countries.


Cambridge House Investor Conference

Verisante also announced the Company will be exhibiting at the Cambridge House Investor Conference in Vancouver, BC on June 1 and 2, 2014. Interested parties may visit the Company at our information booth (#618) where investors where Aura™ will be displayed.

Thomas Braun will also be presenting to investors at 9:50am on June 1 and 9:40am on June 2.


About Astoria Capital

Astoria Capital invests in and helps finance innovative young life sciences and technology companies with a particular focus on licensing technologies and forming joint ventures with companies from North America in order to help commercialize those technologies in Europe and around the world. Astoria Capital employs a highly disciplined due diligence process that balances risks with growth potential. It rigorously accesses management's historical track record and level of commitment. Astoria Capital carefully weighs the variables that can enhance or impede management's ability to execute. It calculates the timing and economics of scalability and the range of risk reward probabilities. Additional information is available on the company's website: www.astoriacapital.pl


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[M@trix]

Endlich ein Weg mit dem Vertrieb nach vorne zu kommen, ohne unmittelbare weitere Verisante-Aktien platzieren zu müssen. Dennoch muss ich zugeben, dass mir die Vermarktung weiterhin viel zu langsam voran kommt. Das hat indes die Börse auch schon entsprechend eingepreist bei nur noch 14,3 Mio. CAD Börsenwert... Insofern aus meiner Sicht nun ein exzellentes Chance/Risiko-Verhältnis.

Dazu ergänzend:

TLSR: Cancer detection is a stable topic in any biotech investment model. Do you have any hot picks in that space?

JW: Verisante Technology Inc. (VRS:TSX.V) is headquartered where I am, in British Columbia. The company's platform was developed in partnership with the University of British Columbia and the BC Cancer Agency. Verisante's technology, now commercially available, has revolutionized the diagnosis of skin cancer. Its product is called the Aura. And the company's complementary product, the Core detection system, detects internal cancers, such as lung, kidney, and bladder cancers. Core is undergoing regulatory testing for licensing in Canada and Europe, and Verisante soon will seek U.S. Food and Drug Administration (FDA) approval for Core.

TLSR: How do these products work?

JW: Verisante's skin cancer detection technology spectroscopically analyzes skin blemishes that could be cancerous growths and, within one second, delivers a result with 99% accuracy. This is a vast improvement over the current technology, based on biopsies that puncture the skin and can infect healthy skin tissue in the process. Biopsy results have to be sent off to a laboratory and can take up to two weeks to come back. The key to survival is early detection. With the Aura system, a doctor can take a light spectroscopic image and compare it to a database to quickly make a diagnosis.

TLSR: What does the Aura system look for?

JW: It shines light through cells and analyzes changes in the color spectrum of the reflected light. Different cellular compositions have different light reflection characteristics, and cancerous cells can be quickly identified.

TLSR: When can we expect Aura to be on the market?

JW: Verisante has already sold several Aura units in Canada. Its sales force is rolling out a marketing program in Canada and Europe, where the product is also licensed. It is expecting word on FDA approval before the end of 2014, which will enable the company to market Aura in the U.S. It is still early days, though, and Aura is not widely known within the industry. The real momentum in the marketing program is yet to be realized.

TLSR: Can a local doctor's office buy the Aura machine?

JW: Verisante leases the Aura system to doctors. It only takes four diagnoses to break even on the lease cost of the unit. Aura is designed as a floor model with a small footprint that can occupy a corner of a doctor's office. The doctor can offer skin cancer diagnostics onsite, with an instant-turnaround result, for a very reasonable cost that is covered by medical insurance plans in Canada and Europe. That coverage is, as yet, uncertain in the U.S.

TLSR: How does Core work?

JW: The Core detection system uses a similar spectroscopic approach to Aura. But the Core device attaches to the end of an endoscopic probe that can be introduced into the body internally and analyzes lesions for malignancy on the spot. It is primarily designed to detect lung cancers, but Verisante is creating variations that will detect other forms of cancergastrointestinal, colorectal, cervical, bladder.

TLSR: And Core is on the market now?

JW: Core is not yet on the market. Verisante has just completed an International Organization for Standardization (ISO) quality recertification for use in Canada. Currently, the company has applications for approval for use pending in Canada, Europe, the U.S. and in China for lung cancer, specifically.

TLSR: How has Verisante's stock been responding to the company's achievements?

JW: Verisante trades on the TSX.V, so it has been painted with the mining company stigma that all TSX.V companies struggle with presently, since more than half of the constituents of the TSX Venture Index are mining companies. The stock has been trading sideways within a range of $0.140.24/share for the better part of the last six months. This strikes me as a great point of entry. Verisante has a very advanced technology that is market-ready and already approved in Canada and Europe. The catalyzing event will be FDA approval in the U.S., which will attract the interest of larger pharmaceutical device companies attracted to the low valuation. I covered Verisante in the April edition of The Midas Letter, and the response was terrific.

http://www.itbusinessnet.com/articles/viewarticle.jsp?id=328…

[Popeye82]

Edison Research Initiates Coverage on Verisante Technology, Inc. - Jun 3, 2014
www.edisoninvestmentresearch.com/research/company/verisante-…

[M@trix]

Ich bin mit Verisante "nicht mehr so im Reinen". Das Management hat in den vergangenen 2 Jahren aus meiner Sicht sehr viel Geld unnötig für PR verschleudert und m.E. zu blauäugig angenommen, dass Auszeichnungen zu Umsatz und Interviews zu Aktiensteigerungen bzw. nachhaltig neuen Investoren führen würden.

Als ich den jüngsten Management Report gelesen habe, wurde mir ganz anders als ich las, dass Brown&Co inzwischen auf ihr Gehalt "verzichten"... Verisante braucht dringend neues Kapital und dann Sales, Sales, Sales. Die Produkte sind sicherlich ein Meilenstein in der Krebsvorsorge, aber sie müssen auch bezahlbar sein und gekauft werden. Ich bin gespannt, ob Brown das hinbekommt, bin jedoch weitaus nicht mehr so optimistisch wie vor einigen Monaten noch. Indes bin ich damit nicht allein, wie der Börsenwert zeigt...

M@trix

[Popeye82]

Verisante Technology, Inc. Partners with the BC Cancer Foundation, to Showcase Aura™ for Skin Cancer Detection - Jun 10, 2014
www.verisante.com/news/134/verisante-technology-inc-partners…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 10, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company is partnering with the BC Cancer Foundation to showcase Verisante Aura™, a device for the detection of skin cancer.

"We are very appreciative of the BC Cancer Foundation's support for Verisante and for Aura™ and also for the Foundation's dedication to raising funds that support innovative research directed at achieving the highest standard of care for every patient facing cancer in B.C.," said Thomas Braun, President & CEO of Verisante Technology, Inc.

Verisante has placed an Aura™ at the Foundation's Provincial Office in Vancouver for display and educational purposes.

"Our unique relationship with the BC Cancer Agency allows our donors to be part of research discoveries made right here in British Columbia," said Douglas Nelson, President & CEO of the BC Cancer Foundation. "Verisante Aura™ is one of those 'made in BC' inventions coming out of the leading edge technology and research efforts of the BC Cancer Agency. Our Foundation is pleased to have the opportunity to demonstrate and promote this exciting technology."

The BC Cancer Foundation funds the areas of greatest priority and promise, as identified by the scientists and clinicians at the BC Cancer Agency, who look for priorities and needs that will have the most significant and timely impact on cancer care and treatment. The Foundation then partners with donors to raise the necessary funds in support of this life-saving work. Together with its partners, the Foundation is funding and finding solutions that are having a direct impact on improving care for cancer patients in British Columbia.


About the BC Cancer Foundation

The BC Cancer Foundation is the bridge that connects philanthropic support and research breakthroughs in cancer knowledge. As the fundraising partner of the BC Cancer Agency and the largest charitable funder of cancer research in this province, we enable donors to make contributions to leading-edge research that has a direct impact on improvements to cancer care for patients in British Columbia. We fund with the goal of finding solutions.

As an independent charitable organization, we raise funds exclusively for the BC Cancer Agency that support innovative cancer research and compassionate enhancements to patient care.

Visit www.bccancerfoundation.com to make a donation or to learn how you can make a difference in the lives of those affected by cancer.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[Popeye82]

Verisante Technology, Inc. Announces Non Brokered Private Placement +'Letter of Intent', for the Exclusive Sales +Marketing Rights for Cancer Detection Technology, in China - Jun 25, 2014
www.verisante.com/news/135/verisante-technology-inc-announce…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 25, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it has closed a non-brokered private placement of 2,000,000 common shares at a price of $0.15 per share for gross proceeds of $300,000.

The private placement comes in conjunction with the signing of a Letter of Intent between the Company and a strategic partner (the "Partner") to grant the exclusive marketing and sales rights, in The People's Republic of China, for the Core™ for lung, colon, cervical and nasal cancer detection, and for the complimentary ClearVu endoscopic camera (the "Definitive Agreement").

Under the terms of the Letter of Intent, the Definitive Agreement will be contingent upon the Company receiving an additional $2.5 million investment via private placement by the end of September, 2014. The private placement shall be for common shares (with no warrants) with a discount to the market price of no greater than 15%. The Partner will separately fund the SFDA approval process for regulatory approval in The People's Republic of China, for the products starting with the Core™ for lung cancer, including funding clinical studies, if necessary.

"This is a major breakthrough for Verisante in the biggest market in the world for lung cancer. China has approximately one third of the lung cancer cases in the world, is currently the second largest buyer of medical devices globally, and is expected to surpass the USA in that regard sometime in the next ten years," said Thomas Braun, President & CEO of Verisante. "With so many patients and 21,000 hospitals, we are very excited to have a strategic partner who will provide capital for Verisante and separately fund the SFDA approval process for the Core™. This new capital will also advance Aura™ (for skin cancer detection) into the US FDA approval process, and we look forward to achieving these major market approvals for our game changing technology."

The private placement is subject to all necessary regulatory and stock exchange approvals. Securities issued pursuant to the private placement are subject to a hold period of four months plus one day from the date of distribution. Net proceeds of the private placement will be used for working capital requirements. No finder's fee was paid in connection with this private placement.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, GI tract and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[Popeye82]

Verisante Technology, Inc. Welcomes Dr. Kenneth Beer +Dr. Philip Werschler onto Clinical Advisory Board - Jul 29, 2014
www.marketwired.com/press-release/verisante-technology-inc-w…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 29, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, is pleased to welcome Dr. Kenneth Beer, MD, PA and Dr. Wm. Philip Werschler, MD, FAAD, FAACS, onto the Company's Clinical Advisory Board.

"Both Dr. Beer and Dr. Werschler have extensive experience assisting companies with setting up scientific advisory boards, advising with clinical studies and navigating the medical device regulatory regime in the United States," said Thomas Braun, President & CEO. "We are fortunate to have two experts in their field join our Advisory Board and look forward to working closely together to further the objectives of Verisante."

Dr. Beer is a Florida based board certified dermatologist and dermatopathologist who has served the Palm Beach, Broward and Martin area for over 15 years, with offices in West Palm Beach and Jupiter. He is also a Fellow of the American Academy of Dermatology, a Fellow of the American Society of Dermatologic Surgery, volunteer assistant professor at the University of Miami, Consulting Associate with the Department of Medicine at Duke University and a member of the Thoracic Cancer Society.

"Verisante's technology certainly has the potential to make a significant impact on the clinical setting and patient outcomes when it is introduced into the United Stated," said Dr. Beer. "Not only can Aura™ meet the need for dermatologists and physicians' with a skin specialty to have better tools to assist in diagnosing skin cancer, but as member of the Thoracic Cancer Society, I see the applications for the Core™ technology to be highly disruptive in the field."

Dr. Werschler, also a board certified dermatologist and skin cancer surgeon, is an internationally recognized expert in both medical and cosmetic dermatology/aesthetic surgery, and in this capacity he has been honored to serve as a FDA investigator for clinical trials of both drugs and devices throughout his career. Today, nearly all of the FDA approved aesthetic injectable dermal fillers and toxins were tested in his research center, Premier Clinical Research, in Spokane, WA. Dr. Werschler also has extensive experience in the conduct of investigative clinical trials for both precancerous lesions and skin cancers.

"I have been following Aura™ with intense interest for several years now, and look forward to assisting in any investigative clinical trials that might be necessary to bring this exciting technology to the United States. The opportunity of non-invasive diagnosis for skin cancer is potentially a complete game changer in the clinical practice of dermatology and cutaneous oncology. The Aura™ combines emergent technology with patient friendly evaluation of suspicious skin lesions for both melanoma and non-melanoma skin cancers. Any tool that can help a doctor become better at assessing skin cancer can only be a benefit to both doctors and patients", said Dr. Werschler.


About Dr. Kenneth Beer, MD, PA

Dr. Kenneth R. Beer, MD PA is board certified in both dermatology and dermatopathology, the microscopic study of the skin. He is one of the few cosmetic and surgical dermatologists to be credentialed in both specialties. Dr. Beer completed his residency in dermatology and fellowship in dermatopathology at The University of Chicago. He is a voluntary assistant professor at the University of Miami and a consulting associate in the Department of Medicine at Duke University.

Dr. Beer has authored numerous publications including several scientific articles and chapters in textbooks of Cosmetic Surgery and Dermatology. Among the publications Dr. Beer has published are articles comparing various topical creams with Botox, different types of fillers used to treat nasolabial creases and a host of others that have advanced the field of dermatology. He is renowned as one of the country's top experts in Botox and has published extensively in cosmetic dermatology journals, including "Cosmetic Dermatology," "Dermatologic Surgery" and is the author of the monthly "Cosmetic Clinic" for dermatologists that appears in "Skin and Aging" magazine. By combining his dermatology and dermatopathology expertise, Dr. Beer has become a leader in skin cancer surgery and reconstruction as well as cosmetic dermatology.


About Dr. Wm. Philip Werschler, MD, FAAD, FAACS

Dr. Wm. Philip Werschler MD is the founding member of Spokane Dermatology Clinic and Werschler Aesthetics. Dr. Werschler has been an active teaching member of the University of Washington faculty for over 20 years, where he serves as a Clinical Professor in Medicine/Dermatology. A graduate of the George Washington University, School of Medicine, Washington, D.C. He is affiliated with several professional societies, including a full fellow of the American Academy of Dermatology, the American Academy of Cosmetic Surgery, American Society for Dermatological Surgery and the American Society for Mohs Surgery.

Dr. Werschler has contributed extensively to the dermatologic literature and is the founding aesthetic Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, a leading PubMed listed specialty journal. Dr. Werschler is also the Editor-in-Chief of Cosmetic Dermatology, the specialty's original journal for cosmetic and aesthetic dermatology. He is on the editorial boards of multiple scholarly journals including Skin and Aging, Cutis, and the Journal of Drugs in Dermatology. Dr. Werschler lectures both nationally and internationally on advances in the field of dermatology, aesthetic medicine and surgery.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[wallstone]

Antwort auf Beitrag Nr.: 47.393.286 von Popeye82 am 29.07.14 18:52:04

Es bewegt sich ja was, auf dem aktuellen Niveau scheint sich der Kurs zu stabilisieren.

[Popeye82]

Antwort auf Beitrag Nr.: 47.209.766 von Popeye82 am 25.06.14 20:20:00

Verisante Technology, Inc. Announces Re-Negotiated 'Letter of Intent' for Equity Stake in Chinese Company - Sep 30, 2014
www.verisante.com/news/138/verisante-technology-inc-announce…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 30, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it has renegotiated a Letter of Intent between the Company and strategic partner (the "Partner") in the People's Republic of China, which terms were previously announced on June 25, 2014.

Under the terms of the new Letter of Intent, Verisante will enter into a Definitive Agreement to sublicense the world-wide rights to develop and commercialize the Core™ Raman technology with the ClearVu™ endoscopic camera system for the detection of lung cancer, and the China marketing rights for other Core™ series products (subject to existing agreements) into an LLC Company in China (the "LLC").

Verisante will received a 30% equity stake in the LLC, and the parties agree to list the LLC onto the Chinese OTC market as soon as the LLC meets listing standards, with the longer term goal of upgrading the LLC onto the ChiNext Tire of the Shenzhen Stock Exchange.


Other material terms of the Letter of Intent include:

- The Partner agreeing to an equity investment of $2,150,000 into Verisante over the next 24 months ($300,000 of which has already been invested in a previously announced private placement);
- The LLC agreeing to fund the development and commercialization of the Core™ device for lung cancer, including all regulatory costs associated with medical device approvals in China;
- The LLC agreeing to pay Verisante a $1 million development fee upon regulatory approval and sale of the LLC's first Core™ product; and
- Verisante agreeing to oversee manufacturing and supply of the Core™ for lung cancer to the LLC.


"The amendment to our original Letter of Intent to create a newly listed Chinese Company will allow greater access to the Chinese capital markets to be able to fund the development and commercialization of our Core™ technology for lung cancer", said Thomas Braun, President & CEO of Verisante. "China has approximately one third of the lung cancer cases in the world, and is currently the second largest buyer of medical devices globally. This commitment of stable capital flow over the next 24 months will also advance Aura™ (for skin cancer detection) into the US FDA approval process, and support continued sales and marketing for Aura™ in territories where the device is already approved."


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, GI tract and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[M@trix]

Verisante Technology, Inc. Announces Submission to the FDA for Aura(TM), a Skin Cancer Detection Device

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 1, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it has initiated communications with the Food and Drug Administration ("FDA") in the United States for the approval of Aura™, a device for the detection of skin cancer.

"Verisante has now submitted documents to the FDA as we begin the formal application process for approval to market and sell Aura™ in the United States," said Thomas Braun. "We look forward to working closely with the FDA to receive further guidance and feedback on our regulatory pathway."

According to the Skin Cancer Foundation, skin cancer is the most common form of Cancer in the United States, with more than 3.5 million skin cancers in over two million people diagnosed annually. Every year the new cases of skin cancer are greater than the incidences of breast, prostate, lung and colon cancer combined.

Melanoma, the deadliest form of skin cancer, accounts for one death every 57 minutes in the United States. The overall 5-year survival rate for a patient whose melanoma is detected early, before the tumor has spread, is about 98 percent but falls to 62 percent when the disease reaches the lymph nodes, and 16 percent when the disease metastasizes to distant organs.

http://www.wallstreet-online.de/nachricht/7049687-verisante-…

[Popeye82]

Verisante Technology, Inc. Announces Equipment Loan, to Further Collaboration With 'Key Chinese Laboratory' - Feb 18, 2015
www.verisante.com/news/144/verisante-technology-inc-announce…

"VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 18, 2015) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it has expanded its collaboration with Fujian Normal University in China (the "University").


Verisante has signed an equipment loan agreement with the Key Laboratory of Optoelectronic Science and Technology for Medicine, Ministry of Education, at Fujian Normal University. The Company will loan two of its Raman spectrometers to the Laboratory for the testing of a new probe design which stands to decrease the cost of the Company's endoscopic Raman system for early cancer detection by 50%.

The Company has previously announced a collaboration and equipment loan to the University as well as a Letter of Intent (LOI) with Chinese investors to set up a new company in China to commercialize the Company's endoscopic products for cancer detection first in China, and then the rest of the world.

"I was recently in China to meet with University researchers and our new investors. With one third of lung cancers globally, China is the biggest market for our endoscopic products, and the place where we can make the biggest impact in our fight against cancer," said Thomas Braun, CEO. "I was very impressed with the high quality of the labs at Fujian Normal University and am very excited about the overall progress we are making in China towards introducing our device for lung cancer detection."

Pursuant to the previously announced LOI, the Company is currently working with its strategic partners to incorporate a new company in China that will be the vehicle for commercialization of its endoscopic cancer detection system with lung cancer being the first focus. Once this new company is created it will establish offices in China for the purpose of managing a clinical trial in China for lung cancer detection.


About Fujian Normal University

Fujian Normal University, founded in 1907, is one of the largest universities in Southeastern China. The University has four national centers for scientific research and personnel training, eight key laboratories or research centers sponsored by either the ministries concerned or the provincial government, one Ministry of Education sponsored research center for basic education, and several dozens of provincially sponsored laboratories and research institutes. The nasopharyngeal research will be led by Professor Rong Chen as principal investigator at the Key Laboratory of Optoelectronic Science and Technology for Medicine, Ministry of Education.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. "

[M@trix]

World first as surgeons spot a brain tumour - with a 'bleeping pen': Laser helps surgeons tell the difference between healthy and cancerous tissue

British surgeons use pen-like probe to spot brain tumours for the first time
Laser helps medics tell difference between healthy and cancerous tissue
Pioneering technique could shave 30 minutes off three-hour operations



"Senior neurosurgical trainee Babar Vaqas, who spearheaded the project to bring the Core to the UK, says: ‘There really is nothing like this at the moment.
‘Brain surgery is a very complex operation – sometimes even taking just a millimetre too much can cause real damage, such as paralysis or problems with speech. Having something that will make surgery safer and more accurate could be a real game-changer.’ [...]

‘Having a device that takes less than a second to tell the difference between healthy and cancerous tissue means we could potentially avoid taking unnecessary biopsies, and also perform more surgeries in a day,’ he says.
The Core’s makers, Canadian company Verisante Technology, hopes the work at Imperial will replicate the success of a similar trial used to detect skin cancer on 1,000 patients at a hospital in Vancouver.

The Imperial trial is being part-funded by charity Brain Tumour Research Campaign, which claims research into diagnostics and treatment is ‘woefully underfunded’.
Founder Wendy Fulcher says: ‘Taking away healthy tissue can have disastrous consequences, so this probe is hugely exciting.’"

http://www.dailymail.co.uk/health/article-3015974/World-surg…


Ich war schon immer der Ansicht, dass "CORE" der eigentliche Blockbuster werden könnte und Verisante dafür "Aura" vollständig an Dritte auslizensieren sollte.

M@trix

[M@trix]

Zuletzt gab es einige Artikel zur Technologie, Verisante wurde jedoch nicht namentlich genannt. Beispiel:

Hirn-Chirurgie
Mit Laserlicht auf Tumorjagd

"Chirurgen haben erstmals in Europa einen Patienten mit einer Lasertechnik behandelt, die während einer Gehirntumor-Operation krebskrankes von gesundem Gewebe unterscheidet. Anhand der Reflexion der Strahlen konnten die Londoner Ärzte erkennen, wo genau das Gehirn von Krebs befallen war.

Die neue Technik ermöglicht Chirurgen, in Sekundenschnelle zu entscheiden, wo sie schneiden sollen. Bisher müssen dafür während der Operation Gewebeproben im Labor untersucht werden."

http://www.wiwo.de/hirn-chirurgie-mit-laserlicht-auf-tumorja…

Hier wird Verisante indes erwähnt:

Laser probe and smart knife 'improve accuracy of removing brain tumors'

"Neurosurgeon Babar Vaqas, who is leading the trial at Imperial College Healthcare NHS Trust, says:

"Being able to use both of these innovative technologies during delicate brain surgeries is considerably improving the accuracy of removing brain tumors. This means that patients are far less likely to suffer from the side effects of cutting away healthy tissue such as loss of speech."

The laser probe, which uses Raman spectroscopy to analyze the light scattered from the tissue, is provided by Verisante Technology, Inc., of Vancouver, Canada.

Vaqas says the trial is the first ever application of Raman spectroscopy during human brain surgery."

http://www.medicalnewstoday.com/articles/298657.php

Aus meiner Sicht ist die Technologie bahnbrechend, das Problem für den Aktionär liegt im mangelnden kommerziellen Erfolg.

Börsenwert indes nur noch 7,8 Mio. CAD. Denke Verisante wird irgendwann aufgekauft.

M@trix